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Abstract 
Chronic obstructive pulmonary disease (COPD) is a major contributor to hospitalizations 
and healthcare costs in North America.  While the hallmark of COPD is airflow limitation, 
it is also associated with abnormalities of the cardiovascular system.  Enlargement of the 
pulmonary artery (PA) is a morphological marker of pulmonary hypertension, and was 
previously shown to predict acute exacerbations using a one-dimensional (1D) diameter 
measurement of the main PA.  We hypothesized that a three-dimensional (3D) 
quantification of PA size would be more sensitive than 1D methods and encompass 
morphological changes along the entire central PA.  Hence, we developed a 3D 
measurement of the main (MPA), left (LPA) and right (RPA) pulmonary arteries as well 
as total PA volume (TPA) volume from thoracic x-ray computed tomography (CT) 
imaging. Three observers performed five repeated measurements for 15 ex-smokers.  There 
was a strong agreement (r2 = 0.76) between PA volume and PA diameter measurements, 
which was used as the gold standard. Intra-rater measurement reproducibility was 
evaluated by calculating the coefficient of variation (CV) using five rounds of 
measurements and revealed excellent agreement (CV < 8%) between measurements. Inter-
rater measurement variability was also evaluated using intraclass correlation analysis 
which revealed strong agreement (ICCMPA=0.98) between observers.   
In an application of this tool, we sought to explore the relationship between PA volumes 
and lung structure-function as determined by spirometry, hyperpolarized helium-3 
magnetic resonance imaging (MRI) and CT in 124 ex-smokers, with (n=68) and without 
(n=56) airflow limitation, and in a control group of 35 healthy never-smokers.  We 
observed significantly greater MPA (p=.014), RPA (p=.001) and TPA (p=.003) volumes 
in ex-smokers with airflow limitation when compared to ex-smokers without airflow 
limitation.  We also observed significantly greater PA volumes in both ex-smoker 
subgroups when compared with the never-smoker control group. Modest but significant 
correlations were observed for PA volumes and measurements of lung structure and 
function.  However, this was not observed when analyzing ex-smokers with airflow 
limitation alone, suggesting that pulmonary artery enlargement may occur secondary to 
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COPD in our subject group.  Multivariate zero-inflated Poisson regression analysis 
revealed TPA volume to be a significant (p=.03) predictor of acute exacerbations of COPD. 
In conclusion, we developed a reproducible technique for quantifying the volume of the 
PA. We showed that pulmonary artery enlargement may be secondary to COPD in our 
subject group. We also showed that total pulmonary artery volume was a significant 
predictor of COPD exacerbations and could be considered as a biomarker for predicting 
the occurrence of exacerbation events.  Automated measurements of pulmonary artery 
abnormalities once developed, can be used to further evaluate healthy volunteers and 
patients with COPD.  
Keywords: Chronic obstructive pulmonary disease (COPD), cardiovascular disease, 
pulmonary artery, enlargement, main pulmonary artery volume, left pulmonary artery 
volume, right pulmonary artery volume, total pulmonary artery volume 
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CHAPTER 1: INTRODUCTION  
Individuals with Chronic Obstructive Pulmonary Disease (COPD) often experience acute 
exacerbations which are severe events associated with an increase in morbidity and 
mortality.  Previous work1 demonstrated that abnormalities of the pulmonary artery are 
predictive of these events; however, further research and better tools are needed to 
strengthen this finding.  The purpose of this chapter is to provide motivation for the work 
presented in subsequent chapters and to provide an overview of pulmonary anatomy, lung 
function, pulmonary artery anatomy and current biomarkers used to predict the occurrence 
of acute exacerbations of COPD.   
 Overview 
Chronic obstructive pulmonary disease (COPD) is a chronic, obstructive, inflammatory 
disease affecting millions of individuals.  It mainly manifests in elderly individuals who 
have been exposed to tobacco smoke and air pollution for extended periods of time.2  These 
toxins induce an inflammatory response in the lungs, resulting in a combination of small 
airways disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the 
extent of which varies among individuals.3  Persons with COPD are associated with a 
decline in lung function and an increase in airflow limitation.  As the disease progresses, 
those with moderate-to-severe disease are likely to experience acute events known as 
exacerbations, often resulting from bacterial or viral infections.4  These individuals 
experience a reduced quality of life and seek immediate medical attention which often 
results in hospitalization.  Costs associated with treatment substantially burden our 
healthcare system.  While COPD is preventable and treatable, it is very rarely reversible.  
Current diagnosis relies on spirometry measurements as it is the most widely available 
diagnostic tool that can provide global measurements of the lung.   
Although the defining feature of COPD is airflow limitation, COPD is also associated with 
vascular abnormalities such as coronary vascular disease, cerebrovascular disease5-8 and 
pulmonary artery (PA) anomalies.1  Vascular disease is the leading cause of hospitalization 
for individuals with mild to moderate cases of COPD and following cancer, it ranks as the 
second leading cause of death.9, 10  Those with COPD can often develop mild cases of 
pulmonary hypertension (PH), while some can progress to develop out of proportion PH, 
which has also been linked to abnormalities in the PA.11  While previous studies have 
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utilized a simple one-dimensional diameter measurement of the main PA (MPA) to 
quantify its size, a more robust, three-dimensional (3D) measurement for assessing PA 
volumes has not yet been developed.  Thus, our goal was to develop 3D metrics to evaluate 
the size of the main, left (LPA) and right (RPA) pulmonary arteries and to explore their 
relationships with measurements of lung function and structure as determined by 
spirometry, CT and hyperpolarized helium-3 magnetic resonance imaging (MRI) of the 
lung.   
The second chapter of this thesis focuses on the development of the 3D measurement for 
quantifying MPA, LPA, RPA and total PA (TPA) volumes.  Intra- and inter-observer as 
well as longitudinal reproducibility was assessed and reported.  The third chapter focuses 
on the relationship between MPA, LPA, RPA and TPA volumes with measurements of 
lung function and structure as well as on the ability of the 3D volumetric technique in 
predicting future exacerbations of COPD.  The fourth and final chapter of this thesis serves 
as a summary.  As well, it focuses on the limitations of the current techniques outlining 
ideas that might be worth exploring in the future.  
 Burden of COPD 
As outlined by The Global Burden of Disease set by the World Health Organization, 
respiratory disease accounted for 6.8 and 6.9 percent of female and male deaths 
worldwide.12  Furthermore, COPD has ranked as the fourth leading cause of death 
worldwide accounting for 3.0 million or 5.1% of all deaths worldwide.12  In 2012, COPD 
was ranked as the fourth leading cause of death in lower-middle income countries, next to 
ischemic heart disease, stroke and lower respiratory infections, causing a total of 3.1 
million deaths worldwide.13  To date, there are 64 million people who suffer from mild-to-
moderate cases of COPD and this number is on the rise.  Projections for 2030 predict COPD 
to climb to be the third leading cause of death worldwide, accounting for 8.6% of all deaths, 
a 3.5% increase from 2004 in total deaths due to COPD.14  The leading causes of death for 
2004 and projections for 2030 are summarized in Table 1-1.  Interestingly, vascular disease 
is the single largest cause of hospitalization for individuals with mild-to-moderate cases of 
COPD, and following lung cancer, the second leading cause of death.9, 10  In a recent study9 
of 5887 middle-aged volunteers with asymptomatic airway obstruction who quit smoking 
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at the baseline visit, 22% of subject deaths were caused by cardiovascular disease, second 
to 33% of lung cancer deaths, 14.5 years into the study.9  Thus, it is important to consider 
and explore in detail the relationship between COPD and cardiovascular disease to better 
understand the mechanisms responsible for such outcomes.   
Table 1-1 Leading causes of death as determined by the WHO.14 
Disease or Injury          2004           2030 
 Deaths (%) Rank Rank Deaths (%) 
Ischemic heart disease 12.2 1 1 14.2 
Cerebrovascular disease 9.7 2 2 12.1 
Lower respiratory infections 7.0 3 4 3.8 
COPD 5.1 4 3 8.6 
 Lung Structure and Function 
Human cells require oxygen from the surrounding environment to produce energy in the 
form of adenosine triphosphate (ATP) through a process called cellular respiration.  A 
byproduct of this process is carbon dioxide, which must be removed and released back into 
the environment.15  The primary function of the lungs is gas exchange, delivering oxygen 
from the environment into our circulating blood as well as removing carbon dioxide and 
releasing it back into the environment.16  Figure 1-1 outlines the human airway tree, the 
path inhaled air takes to reach the alveolar sacs (alveoli) of the lungs, where the majority 
of gas exchange occurs.  The airways are made up of branching tubes which become 
progressively narrower and shorter and increase in number towards the alveolar sacs.16  
Airways can be divided into two major categories, those in the conducting zone and those 
in the respiratory zone.  Conducting airways are responsible for transporting air to smaller 
airways where gas exchange can take place.  Conducting airways are not responsible for 
gas exchange as they do not contain alveoli.16  Respiratory airways however contain alveoli 
and therefore are responsible for gas exchange.  Most of the gas exchange occurs in the 
alveoli which are the most distal part of the airway tree.16  The following subchapters will 
outline the roles of the conducting and respiratory airways in more detail.  
1.3.1 Conducting zone 
The conducting zone is comprised of the upper and lower airways.  The upper airways 
include the nose, oral cavity, pharynx and the larynx.17  They are responsible for being the 
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primary conductors of air, for warming and humidifying the inspired air and for preventing 
foreign materials from entering the airways.17  Following the upper airways, inhaled air 
travels through the lower airways (conducting airways) which in general include the first 
16 generations (orders) of the tracheobronchial tree.16, 17  As shown in Figure 1-1, the 
airway tree starts off at generation zero, or the trachea, which then divides into the left and 
right main bronchi which enter the left and right lung respectively.16  The airway tree 
continues dividing in a dichotomous fashion, meaning that every mother branch bifurcates 
into two daughter branches, that can be different in size, first into bronchioles and then the 
terminal bronchioles.15, 16, 18  The terminal bronchioles are generally the 16th generation 
airways and are the final airways that make up the conducting zone.  Besides directing air 
to the respiratory zone, the conducting airways further warm and humidify the inhaled air 
to make it more efficient for gas exchange.  The walls of these airways are generally 
composed of three different layers.  The inner epithelial layer is lined with epithelial cells 
that are equipped with cilia and numerous mucus glands.  These form the mucociliary 
escalator and work together to expel foreign particles.15, 17  Trapped particles in the mucus 
travel upstream at a rate of about 2 mm/s to the pharynx, where the mucus is swallowed.15  
The middle layer of the wall is a smooth muscle layer while the outermost layer is 
composed of connective tissue containing supportive cartilage.15  Both layers provide the 
conductive airways’ rigidity and support.  Due to the lack of alveoli, the conductive airways 
do not play a role in gas exchange.  Thus, they constitute the anatomic dead space which 
is about 150 mL in volume.16   
1.3.2 Respiratory zone 
The respiratory zone is comprised of airway generations 17 to 23.  The respiratory 
bronchioles are the first airways to form alveoli and therefore some of the gas exchange 
occurs in these airways.16  As shown in Figure 1-1, downstream from the respiratory 
bronchioles, the alveolar ducts form more alveoli and thus, more gas exchange can take 
place in these airways.  Generation 23 is usually the last branch of the airway tree and these 
are the alveolar sacs which are completely lined with alveoli.  This is where most of the 
gas exchange takes place.16  Gas exchange follows simple diffusion, as described by Fick’s 
law of diffusion, outlined in Equation 1 below, where A is the area of diffusion, D is the 
5 
 
 
 
diffusion coefficient of gas, P1 and P2 are the partial pressures of the gas on either side of 
the alveolar membrane and finally, T is the thickness of the membrane.  
𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 =  
𝐴 ∙ 𝐷 ∙ (𝑃1 − 𝑃2)
𝑇
                                                    (1) 
 
Figure 1-1: Human airway tree. This diagram is not drawn to scale. The first 16 
generations represent the conducting zone while generations 17-23 represent the 
respiratory zone of the airways. Image adapted from West JB, Respiratory Physiology; The 
Essentials16 
 
Diffusion of oxygen across the alveolar membrane occurs from an area with high partial 
pressure inside the alveoli to low partial pressure in the pulmonary capillaries.16  Since the 
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alveolar membrane is very thin and has a large area between 50 and 100 square meters, it 
is very well suited for efficient diffusion to occur.16  Since respiratory airways do not have 
a mucociliary escalator like conductive airways, macrophages remove waste and particles 
by carrying them either to the mucociliary escalator or into the bloodstream.15 
 Established methods for measuring lung function 
Several techniques have emerged to assess the function of the lung.  Pulmonary function 
tests provide a quantitative evaluation of global lung function and include spirometry, 
plethysmography and diffusing capacity of carbon monoxide (DLCO).
19  The six-minute 
walk distance (6MWD)20 test provides a means of evaluating exercise capacity and 
breathlessness.  Qualitative measures of lung function include the modified Medical 
Research Council (mMRC) dyspnea scale21 as well as the St. George’s Respiratory 
Questionnaire (SGRQ).22, 23  These tests are relatively inexpensive making them widely 
available and useful tools in the clinical setting as well as in research. In the following 
sections, I will describe these tests in more detail. 
1.4.1 Pulmonary function tests 
Pulmonary function tests provide global measurements of the overall function of the lung.  
Spirometry, which is the most common test and most widely seen in the clinic, measures 
dynamic flow rates using a spirometer (Figure 1-2A) and is the current gold standard for 
measuring lung function.  During a spirometry test, the subject is first instructed to take a 
deep breath all the way in and then is asked to blast the air out as hard and as fast as 
possible, all the way out, through the mouthpiece of the instrument.  This maneuver 
provides us with two parameters, the forced expiratory volume in one second (FEV1), 
which is the amount of air that can be forcefully exhaled in the first second of the maneuver, 
and the forced vital capacity (FVC), which is the total amount of air that can be exhaled 
from the lungs, as shown in Figure 1-2B.  The patient then returns to normal breathing.  
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Figure 1-2: Spirometry measurement. Panel A shows an EasyOne hand-held spirometer. 
To perform a measurement, the subject takes a deep breath all the way in, then is asked to 
blast the air as fast and hard as possible all the way out through the mouthpiece. Panel B 
shows the airflow curve for this maneuver with the forced expiratory volume in one second 
and forced vital capacity overlaid. 
 
 
A plethysmograph, shown in Figure 1-3A, is an instrument which provides a closed system 
environment that measures pressure differences and utilizes Boyle’s law, to calculate static 
lung volumes.  Boyle’s law is shown in Equation 2, where Pl and Vl are the pressure and 
the volume of gas in the lung respectively, while Pb and Vb are the pressure and volume in 
the box. 
𝑃𝑙𝑉𝑙 = 𝑃𝑏𝑉𝑏                                                            (2)                       
 
Volumes that can be obtained using plethysmography are total lung capacity (TLC), the 
total amount of air that is present in the lungs after maximum inhalation; tidal volume (TV), 
the amount of air inhaled and exhaled during regular breathing at rest; functional residual 
capacity (FRC), the amount of air present in the lungs at the end of a normal breath at rest; 
expiratory reserve volume (ERV), the volume of air that can be exhaled after completing a 
regular exhalation at rest; residual volume (RV), the amount of air that remains in the lungs 
after maximal exhalation; inspiratory reserve volume (IRV), the maximum amount of gas 
that can be inhaled after completing a normal inhalation at rest; vital capacity (VC), the 
total amount of air that can be exhaled after the deepest inspiration; inspiratory capacity 
(IC), the total amount of air that can be inhaled after a normal exhalation at rest.  To obtain 
A B 
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these volumes, shown in Figure 1-3B, subjects are instructed to start with normal breathing 
while seated in the closed system.  When they reach FRC a shutter closes, blocking the 
flow of air from entering and exiting the lungs.  As the subject attempts to breathe against 
the shutter, the pressure in the lungs decreases and the volume increases causing the 
pressure in the box to increase and the volume to decrease.  Boyle’s law is then used to 
find the volume of air in the lungs.  
 
Figure 1-3: Static lung volumes. Panel A shows the body plethysmograph that is used in 
our laboratory. This device is used to measure static lung volumes shown in panel B based 
on Boyle’s law. Panel B adapted from Respiratory Physiology.24 
 
To measure gas exchange across the alveolar membrane, a third test which measures the 
diffusing capacity of carbon monoxide (DLCO) can be used.  During this maneuver, the 
subject is instructed to start with normal breathing.  After a few normal breaths, the subject 
is instructed to blow all the way out until RV is reached, and then to breath in quickly. 
During the quick inspiration, the subject inhales a gas mixture with a low known 
concentration of carbon monoxide mixed with tracer gas, generally helium, and air.  After 
a ten second breath hold the subject breathes out and the exhaled gas mixture is analyzed.  
Gas exchange is then calculated based on the difference in concentrations between the 
inhaled gases and alveolar gas sample.19  All of the previously introduced measurements 
 A  B 
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of dynamic flow rates, static lung volumes and gas exchange are often expressed as a 
percent predicted value (%pred) which is calculated based on the gender, age, height and 
ethnicity of the individual being tested.3, 25  
1.4.2 Six-minute walk distance 
The six-minute walk distance (6MWD) is a test to assess exercise capacity according to 
guidelines set by the American Thoracic Society.20  During this test the subject is asked to 
perform walking for six continuous minutes at a normal, comfortable pace along a flat 
corridor with a hard surface.20  The Borg scale26 is used to rate the breathlessness and 
overall physical fatigue before and after the test. Oxygen saturation (SpO2) and heart rate 
are often recorded before and after the 6MWD test even though they are not a mandatory 
component.  Previous studies have shown that 6MWD outcomes correlate well with 
morbidity and mortality.27, 28 
1.4.3 Evaluating dyspnea and quality of life  
As previously introduced, the mMRC21 questionnaire has been developed to assess the 
level of dyspnea of an individual.  The questionnaire ranks dyspnea on a level of Grade 0 
(“I only get breathless with strenuous exercise”) to Grade 4 (“I am too breathless to leave 
the house or I am breathless when dressing or undressing”).21, 29  Previous work has shown 
that the mMRC correlates well with 5-year mortality rates.30  The SGRQ22, 23 is another 
qualitative questionnaire developed for assessing overall quality of life in patients with 
obstructive airways disease.  It evaluates symptoms, activities that relate to breathlessness 
and disturbance of daily life.22  Each of the three topics are given a score ranging between 
zero and one hundred where a high score reflects a poor quality of life.22  
 
 COPD and Acute Exacerbations 
1.5.1 Normal aging of the lung and COPD 
As individuals age, like any other organ, the lung undergoes several important 
physiological changes.  Previous work has shown that over time, there is a decrease in the 
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elastic recoil of the lung, a decrease in the compliance of the chest wall and a decrease in 
the strength of the respiratory muscle.31  Furthermore, it has also been shown that 
individuals over 60 years of age can experience “senile emphysema”, the homogeneous 
enlargement of airspaces without alveolar destruction or chronic inflammation.32  
Individuals with chronic obstructive pulmonary disease (COPD) experience an accelerated 
loss of lung function.  As previously described COPD primarily affects our elderly 
population who have been exposed to tobacco smoke for extended periods of time.3, 33  
COPD is an inflammatory disease which can be broken down into two main conditions 
known as airways disease and emphysema.  During airways disease, the walls of the 
airways are inflamed34 and become thickened.  Mucus secretion is increased, plugging the 
airways and leading to airway obstruction.35, 36  During emphysema, the inflammatory 
response in the lung parenchyma causes destruction of lung tissue leading to alveolar 
enlargement.36, 37  The current definition of emphysema set by the National Heart, Lung 
and Blood Institute states that emphysema is “a condition of the lung characterized by 
abnormal, permanent enlargement of airspaces distal to the terminal bronchiole, 
accompanied by the destruction of their walls and without obvious fibrosis”.38  Emphysema 
and airways disease are two separate conditions in COPD which can occur on their own or 
can coexist and the extent of each can vary amongst individuals.  To diagnose COPD, 
spirometry is used where a post bronchodilator FEV1/FVC < 70% indicates disease and 
disease severity is determined by the FEV1%pred score as outlined in Table 1-2.  
 Table 1-2 Spirometric classification of COPD 
Adapted from Vestbo et al.39 
1.5.2 Acute exacerbations  
As discussed above, COPD exacerbations are often experienced by individuals who are in 
moderate to severe stages of the disease.  Guidelines set by the World Health Organization 
(WHO) and US National Heart Lung and Blood Institute Global Initiative for Chronic 
Stage Severity FEV1 Criteria 
GOLD 1: mild FEV1 ≥ 80%pred 
GOLD 2: moderate 50%pred ≤ FEV1 < 80%pred 
GOLD 3: severe 30%pred ≤ FEV1 < 50%pred 
GOLD 4: very severe FEV1 < 30%pred 
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Obstructive Lung disease (GOLD)3 define a COPD exacerbations as: ‘‘an event in the 
natural course of the disease characterized by a change in the patient’s baseline dyspnea, 
cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and 
may warrant a change in regular medication in a patient with underlying COPD”.3  It has 
been previously shown that the frequency of exacerbations increases with the severity of 
COPD.  Frequency of exacerbations is an independent determinant of health-related patient 
quality of life.40, 41  It has also been shown that exacerbations are associated with an 
increase in inflammatory markers that lead to accelerated disease progression.42, 43  It is 
now believed that exacerbations are primarily triggered by viral and/or bacterial infections 
as well as air pollution.44-47  Individuals are more prone to viral infections through the 
winter months and these types of infections tend to have longer recovery times than 
bacterial infections or those caused by air pollution.48, 49  Current treatment for exacerbation 
depends on the severity of the event and is generally based on the clinical presentation of 
the patient.50  Treatment includes use of short-acting β2-agonist (such as salbutamol) and/or 
ipratropium MDI bronchodilators, corticosteroids such as prednisone, and antibiotics.50-52  
A previous study by Seemungal et al.53 has shown that the median time for recovery from 
exacerbation symptoms is 7 (4 to 14) days; however there are a significant number of cases 
where full recovery to baseline values are not reached.53  A different study demonstrated 
that patients who seek treatment sooner experience a faster recovery and report a higher 
health-related quality of life than those patients with more untreated exacerbations.54  
Evidence shows that about 50% of the exacerbations remain unreported4, 40 which increases 
the risk for requiring an emergency hospitalization.54  Aside from a decreased quality of 
life and increased morbidity of COPD patients, exacerbations also place a huge burden on 
the healthcare system.  In Canada, the total cost for treating moderate and severe 
exacerbations including outpatient treatment, emergency department visits and 
hospitalization services is estimated to range from $646 to $736 million per year.55  This 
amount is primarily attributed to hospitalizations which on average lasted 10 days and cost 
$8669 per individual.55  A different study reported similar findings where the median 
hospital stay was reported to be 9 (5 to 15) days with a median cost of $7100 ($4100 to 
$16000) per individual.56  Costs associated with treating moderate and severe 
exacerbations in the outpatient setting and emergency room are also significant and should 
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be considered.  Treatment of moderate exacerbations in the outpatient setting and 
emergency room on average cost $126 and $515 per visit respectively.55  Similarly, severe 
exacerbations cost $114 and $774 to treat in the outpatient setting and emergency room 
respectively.55  Figure 1-4 outlines the cost breakdown for treating acute exacerbations, 
and as expected, hospitalizations account for the largest proportion of total cost57.  
M e d ic a tio n  3 2 %
C lin ic  v is it 5 .6 %
E m e rg e n c y  4 .4 %
H o sp ita liz a t io n  5 8 % 5 8 %
 
Figure 1-4: Exacerbation cost breakdown. This pie graph shows the costs attributed to 
treating COPD exacerbations. As expected, hospitalizations account for the largest 
proportion of total cost. Image adapted from Chapman et al57 
 
Although frequency of exacerbations was shown to be related to a long-term decline in 
lung function58, there are currently no widely available biomarkers able to predict the 
occurrence of these events.  It has recently been shown that the single best predictor of 
acute exacerbations was the occurrence of previous exacerbations.59  Therefore, there is 
need for new techniques that are able to predict the occurrence of these events for early 
detection and prevention of these episodes, as it would greatly improve patient quality of 
life, slow disease progression and decrease hospital costs associated with treatment.  
Decreasing costs attributed to hospitalization alone could halve the current costs required 
for treating COPD exacerbations.  
Several studies have investigated preventive drugs that could potentially improve patient 
outcomes and reduce the number of hospitalizations.  It has been shown that influenza 
vaccinations and treatment with immunostimulants may lower the number of exacerbations 
and are now recommended for individuals with COPD of significant severity.44, 60-63  Long 
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acting bronchodilators (long-acting beta 2 agonist) such as salmeterol were shown to 
reduce the number of exacerbations over a 3-year period.64  Pulmonary rehabilitation and 
self-management are also believed to reduce exacerbation risk.  Evidence shows that 
exercise training can reduce the length of hospital stays following an exacerbation54 and 
reduce the risk of being re-admitted.65  Finally,  long term oxygen therapy has also been 
shown to reduce the number of hospital admissions, in particular in hypoxaemic COPD 
individuals.66  
 Imaging Lung Function and Structure 
1.6.1 X-ray Computed Tomography 
Plane X-rays were introduced in 1895 as an important imaging modality. However, the 
projection nature of these images limits their use.67  Computed tomography (CT) utilizes 
X-rays to form two dimensional cross-sectional images of the body.67  While Nobel Prize 
recipients G.N. Hounsfield and A.M. Cormack introduced the clinical significance of CT 
in 1972, much of this work relied on theoretical work by J.H. Radon in 1917 and Bernard 
Ziedses des Plantes in 1931.67  The first CT scanner was intended for imaging of the brain, 
but its use was later extended to many different applications with the development of the 
whole body CT scanner in 1975.  CT imaging utilizes X-ray transmission profiles captured 
under a number of different angles through cross sections of the body.67  To capture 
multiple transmission profiles, an X-ray source and detectors are mounted on a gantry 
which rotates around the patient.67  First generation CT scanners acquired multiple X-ray 
profiles for each cross sectional image by rotating 360 degrees around the patient.67  Then 
the patient would be shifted a short distance by moving the table so that the next slice could 
be captured.67  The rotation of the gantry was limited by wires attached to the 
instrumentation on the gantry.  Modern CT scanners have an improved design, such that 
the gantry can rotate an unlimited number of times in the same direction.  With this 
improvement, spiral CT was developed where the patient is translated through the bore of 
the gantry while transmission profiles are captured.67  Modern CT scanners also utilize 
multi-slice detectors along with a fan shaped X-ray beam, allowing for multiple 
transmission profiles to be recorded simultaneously, significantly decreasing acquisition 
time and allowing for whole body imaging within a single breath-hold.67  The CT scanner 
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used to capture images for our studies consists of a 64 slice array of detectors. Panel A of 
Figure 1-5 represents the acquisition pattern of a spiral acquisition, while panel B 
demonstrates the multi-slice aspect of the acquisition.   
 
 
 
Figure 1-5: CT acquisition. The subject is translated through the bore of the gantry while 
the X-ray source and the detectors attached to the gantry rotate freely around the subject. 
Panel A shows the spiral acquisition resulting from this process. Panel B depicts the 
concept of a fan shaped X-ray beam and detectors spanning multiple slices. Image adapted 
from Castellano et al.67 
 
 
Images are reconstructed by intensive mathematical computations, known as filtered back 
projections, of the measured transmission profiles.68  The pixel intensities in the 
reconstructed image are determined based on the corresponding linear attenuation 
coefficients of tissues (µtissue) in the body and are measured in Hounsfield units (HU).  As 
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shown in Equation 3, Hounsfield values are normalized to the linear attenuation coefficient 
of water, thus water has a value of 0HU.  By definition, air is -1000HU, lung is from -
600HU to -950HU, fat is from -60HU to -80HU, soft tissue is from 20HU to 70HU and 
bone is 1000HU or higher.  
 
𝐻𝑈 =
𝜇𝑡𝑖𝑠𝑠𝑢𝑒−𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟
× 1000                                           (3) 
 
Important parameters that are considered when acquiring an image are the rotation time, 
which is the amount of time taken by the gantry to complete a single revolution; the tube 
voltage; the tube current, which is generally limited by overheating of the X-ray tube and 
the scan time; and, the pitch, which is the ratio of table translation per 360 degrees of tube 
rotation relative to the beam width.  All of these factors are optimized such that images of 
sufficient diagnostic quality are achieved while limiting the ionizing radiation that the 
patient is exposed to.   
Computed tomography is the imaging method of choice for lung imaging as it allows for 
the visualization of airways and parenchyma.69-72  Emphysematous lesions in the lung 
parenchyma have lower tissue densities than healthy lung tissue and can be identified by 
regions of lower attenuation values, in Hounsfield units, on density frequency 
histograms.71, 73   The extent of emphysema can be evaluated using a thresh-hold cut-off 
value; the voxels below this value are characterized as emphysematous tissue.  A 
commonly used cut-off is -950 HU, where tissues with attenuation values below -950 HU 
are characterized as emphysema.74 
Airway remodeling in COPD is primarily caused by inflammation in the epithelium of the 
airway wall and mucus plugs in the airway lumen.36 Therefore, airways disease severity 
can also be evaluated using computed tomography by obtaining dimensions of the airway 
wall area and lumen area.75 These measurements are challenging since airway 
inflammation primarily affects the small airways (<2mm in diameter)35, which are difficult 
to visualize using CT.73, 76  
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1.6.2 Magnetic resonance imaging 
Conventional proton magnetic resonance imaging (1H MRI) has become a widely used 
medical imaging modality which relies on the presence of water- and fat- bound hydrogen 
(1H) atoms in the body to acquire images.77  However, due to the relatively low 1H density 
present in the lungs, as shown in Figure 1-6A, the thoracic cavity appears black on 
conventional 1H images, providing little morphological information about the lungs.77  This 
limitation has triggered the development of new MRI techniques for visualizing lung 
function and structure. In particular, the development of hyperpolarized noble gas imaging 
has emerged as a useful technique for imaging the lungs.73, 78  Breath-hold imaging after 
inhalation of hyperpolarized helium-3 (3He) allows for visualization of gas distribution 
within the lungs.77  These images are known as static ventilation images and examples are 
shown in Figures 1-6B and C. Figure 1-6B represents a healthy adult where after inhalation 
of 3He the signal is homogeneously distributed throughout the lungs.  A homogeneous 
signal distribution suggests that all areas of the lung have a homogeneous gas distribution.  
 
Figure 1-6: Proton and hyperpolarized helium-3 MRI of lung. Panel A shows proton 
image of lungs. Panel B shows hyperpolarized helium-3 (3He) MRI overlaid on proton 
MRI for a healthy individual; the inhaled gas is homogeneously distributed in the lungs. 
Panel C shows 3He MRI static ventilation image overlaid on proton MRI for an individual 
with COPD. Areas of signal void in the image represent ventilation defects in the lung. 
 
In contrast, Figure 1-6C shows the signal distribution for an individual with COPD, with 
regions of signal void, known as ventilation defects.  These areas are indicative of poorly 
ventilated or completely unventilated regions in the lung.  Quantitative measurements of 
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ventilation defects have been developed, such as ventilation defect volume (VDV)79 and 
ventilation defect percent (VDP)80 by normalizing static ventilation images to the thoracic 
cavity volume obtain using 1H MRI.  The etiology of ventilation defects is still unclear.  It 
is believed that in COPD they may be due to airway disease, emphysema or a combination 
of both diseases.73  It is also possible that ventilation defects are slow filling regions of the 
lung, relative to the breath-hold scan.  
3He MRI has also been used for evaluating the microstructure of the lungs. Diffusion 
weighted 3He MRI imaging allows for characterization of alveolar size.81-83  By generating 
apparent diffusion coefficient (ADC) maps, alveolar destruction in emphysema can be 
quantified, where higher ADC values represent larger alveolar spaces and therefore greater 
disease severity.82  Higher ADC values are generated for diseased individuals, because the 
gas atoms travel further per unit time.73  Figure 1-7 depicts ADC maps for a healthy subject 
and an individual with COPD where the severity of disease is represented by brighter 
colours. 
 
Figure 1-7: Apparent diffusion coefficient (ADC) maps. Left panel represents a healthy 
individual while right panel represents an individual with emphysema. Brighter colour 
represents higher ADC values.  
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 The Pulmonary Arteries 
The cardiovascular system can be divided into two components, the systemic circulation 
which includes blood delivery between the heart and the organs and tissues in the body, 
and the pulmonary circulation which includes blood delivery between the heart and the 
lungs for re-oxygenation and waste removal.84  The pulmonary arteries (PA) make up the 
first component of the pulmonary circulation.  They are responsible for delivering oxygen-
poor blood from the right ventricle of the heart to the lungs so that it can become re-
oxygenated.85  As shown in Figure 1-8, the main pulmonary artery or the pulmonary trunk, 
leads from the right ventricle of the heart and it divides into the left and right pulmonary 
arteries, supplying the left and right lung respectively.  
 
Figure 1-8: Pulmonary circulation. Black arrows represent the direction of blood flow in 
the heart. De-oxygenated blood leaves the right ventricle of the heart through the main 
pulmonary artery (PA). The main PA then divides into the right and left PAs which then 
divide into three and two lobar arteries respectively. Arteries continue to branch along with 
the airway tree.  Gas exchange occurs in the pulmonary capillaries where diffusion allows 
carbon dioxide (CO2) to be removed from the blood and for blood to get re-oxygenated. 
Oxygenated blood returns to the heart to be transported to the systemic circulation.  
Image adapted from Marieb EN, Human Anatomy.85 
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Each PA then divides into lobar arteries to supply the three lobes of the right and the two 
lobes of the left lung.85  The arteries continue dividing, along with the bronchi and 
bronchioles in the lung, becoming arterioles, and finally pulmonary capillaries at the level 
of the alveoli where most gas exchange occurs.  As previously described, gas exchange 
occurs as determined by Fick’s law of diffusion outlined in Equation 1.  
As shown in Figure 1-9, the walls of the pulmonary arteries are assembled from three main 
layers, each of which have a different composition.  The layer closest to the lumen is called 
the tunica intima layer and is made up of endothelial cells as well as a thin layer of 
connective elastic tissue.17  The composition of the next layer, known as the tunica media, 
changes as the size of the artery becomes smaller.  Larger arteries have media layers made 
of connective elastic tissue, while smaller vessels have media layers made up of smooth 
muscle.17  The smallest arterioles in the pulmonary circulation however, do not have a 
detectable smooth muscle media layer.86  The tunica adventitia is the outermost layer of 
the artery and is made up of connective tissue.  Smaller vessels present in this layer provide 
nutrients for all three layers of the artery.17    
 
Figure 1-9: Layers of pulmonary artery walls. The three main layers that compose the 
walls of pulmonary arteries are the tunica intima, tunica media and tunica adventitia 
moving from the lumen towards the outside of the vessel. 
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 Imaging pulmonary artery abnormalities 
Cardiovascular disease is an important risk factor in individuals with COPD.  Evidence 
shows that it is the single largest cause of hospitalizations and the leading cause of death, 
following lung cancer.9, 10  Specifically, pulmonary vascular disease has been associated 
with exacerbation related hospitalizations as well as mortality.87-89  A common condition 
is the enlargement of the pulmonary artery (PA) trunk and often the right ventricle of the 
heart.  It is believed that in order to re-direct blood-flow to well ventilated regions of the 
lung, hypoxic arteriolar vasoconstriction increases the resistance of the pulmonary 
vasculature, increasing the pressure in the PA trunk and in the right ventricle of the heart.90  
This increase in pressure leads to an enlarged pulmonary artery and a condition known as 
pulmonary hypertension (PH).90  Currently the gold standard for monitoring PH is through 
right heart catheterization; however, this is an invasive technique and can cause 
discomfort.11  The invasiveness of this technique makes it unsuitable for performing 
repeated measurements and therefore unsuitable for evaluating disease progression and 
treatment response.  Therefore, several studies have sought to estimate pulmonary 
hypertension by evaluating pulmonary artery abnormalities using non-invasive imaging 
techniques.  In the following subsections I will discuss different imaging modalities that 
have been considered for evaluating the size of the pulmonary artery.  
1.8.1 Imaging PA using Doppler echocardiography 
Doppler echocardiography is the most common imaging technique for evaluating 
individuals at risk of pulmonary hypertension.91  This non-invasive technique measures the 
peak velocity of the regurgitant jet through the tricuspid valves.91  However, numerous 
studies have explored the relationship between echocardiography and pulmonary artery 
pressures measured using right heart catheterization and have reported poor correlations 
between these techniques.91-94  Therefore, right heart catheterization remains the gold 
standard for evaluating pulmonary hypertension and different imaging approaches have 
been proposed.  
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1.8.2 Imaging PA using plane X-rays 
Pulmonary artery enlargement was first evaluated on X-ray images95-98; however, this 
technique was limited in predicting PH due to the projection nature of plane radiographs.99  
Therefore, these studies relied on measuring the width of the right pulmonary artery to 
evaluate its size as it is situated lateral to the right lower lobe bronchus and is generally 
well distinguished on radiographs.100  However, in cases where the heart is dilated beyond 
the right lower lobe bronchus, the right pulmonary artery is no longer well visible on plane 
radiographs and is more difficult to evaluate.100  Teichmann et al. measured right 
pulmonary artery diameters in 112 healthy individuals as well as 95 men suffering from 
chronic bronchitis.96  They showed that PH could be diagnosed using the width of the right 
pulmonary artery with a reliability of 72.2% in readable films, which dropped to 64.2% 
when including films which were not reliably readable.96  The limitation of plane 
radiographs triggered further research in measuring PA size with the development of x-ray 
computed tomography.  
1.8.3 Imaging PA using X-ray computed tomography 
The limitation of plane X-ray radiographs was overcome by the discovery of X-ray 
computed tomography.  With advances in CT imaging, several studies have revisited the 
relationship between PA size and pulmonary hypertension to determine whether it would 
provide a suitable non-invasive means of assessing patients at risk.  These studies have 
reported a positive correlation between main pulmonary artery diameter and pulmonary 
artery pressure measured using right heart catheterization.11, 99, 101-105  In particular, Lange 
et al. demonstrated that the diameter of the main pulmonary artery measured on chest CT 
images could potentially be used as a biomarker for predicting borderline pulmonary 
hypertension.11  Furthermore, recent findings by Wells et al. suggested that a PA to aorta 
(A) diameter ratio of greater than 1 (PA/A > 1), as measured on chest CT images, was 
significantly associated with a history of acute exacerbations, as well as with risk factors 
of future exacerbations.1  Figure 1-10 shows a representative measurement of the main 
pulmonary artery (MPA) and aorta diameter.  
22 
 
 
 
 
Figure 1-10: Pulmonary artery diameter measurement. Main pulmonary artery (MPA) 
and aorta diameter measurement at the level of the bifurcation. Adapted from Wells et al.1 
 
1.8.4 Evaluating PA abnormalities with magnetic resonance imaging 
Several non-invasive, magnetic resonance imaging (MRI) techniques have been developed 
to estimate pulmonary hypertension, including evaluation of pulmonary artery size.106-110  
Frank et al. found significantly greater main pulmonary artery diameters measured on MRI 
images in 23 hypertensive individuals when compared to a control group (n = 8).106 
Furthermore, Saba et al. showed that the ventricular mass index (ratio of right ventricular 
mass over left ventricular mass) was associated with pulmonary artery pressures measured 
by right heart catheterization.107  Additionally, Tardivon et al. found that in a group of 13 
pulmonary hypertensive individuals, acceleration time (the time from the onset of forward 
flow to the moment of maximum flow velocity in the main pulmonary artery) was strongly 
correlated with pulmonary artery pressure measured using right heart catheterization.108  
Similar results were found by Wacker et al. in a group of 12 hypertensive patients.109 
Finally, Marcus et al. showed a correlation between systolic pulmonary artery pressure and 
acceleration time/ejection time ratio in a group of 12 patients.110  
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 Emerging tools for quantifying pulmonary artery size 
As previously described, current methods for quantifying the size of the pulmonary artery 
rely on a simple one-dimensional diameter measurement of the main PA to assess 
morphological changes of the PA. However a one-dimensional measurement may not be 
sufficient to fully encompass three-dimensional changes of the vessel.  Therefore 
additional research is required to develop more accurate techniques for quantifying the size 
of the PA that would encompass changes of the artery in three dimensions.  Chapter two 
of this thesis describes a three-dimensional method that we developed for quantifying the 
size of the pulmonary artery from thoracic computed tomography images.  It consists of a 
slice-by-slice manual segmentation of each of the main, left and right pulmonary arteries 
in planes perpendicular to the axis of each vessel.  
 Research Hypothesis and Objectives 
As previously described, acute exacerbations of COPD are of major concern because they 
reduce patients’ health-related quality of life and increase patients’ morbidity and 
mortality.  They also account for a large portion of healthcare costs, placing a large burden 
on our healthcare system.  Currently there are no widely available biomarkers that are able 
to accurately predict the occurrence of these events.  Previous work1 investigated the use 
of a one-dimensional diameter measurement of the main pulmonary artery to evaluate 
patients’ exacerbation risk.  However, we believe that a three-dimensional approach would 
be more appropriate for quantifying morphological changes in the pulmonary artery as it 
would account for changes in all three Cartesian planes of the vessel.  Therefore, the 
primary objectives of this thesis were: 1) to develop a three-dimensional measurement for 
assessing the size of the pulmonary artery and test the observer reproducibility and 2) to 
assess the association between pulmonary artery volume and COPD, as well as 
exacerbation frequency.  The purpose of these objectives was to develop a quick and easy-
to-use biomarker that could help improve health-related patient quality of life and reduce 
hospital costs.  
In Chapter 2, our objective was to develop a three-dimensional volumetric measurement 
technique to quantify the size of the main, left and right pulmonary arteries at the level of 
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their bifurcation.  Three observers performed five rounds of repeated measurements to 
evaluate reproducibility.  We hypothesized that measurements will be reproducible with 
low inter- and intra-observer variability as well as with low longitudinal variability.  
In Chapter 3, we investigated the relationship between pulmonary artery volume 
measurements and measurements of lung function and structure in a group of ex-smokers.  
Pulmonary artery volumes of these individuals were also compared to those measured in a 
group of never-smokers.  We also investigated the potential use of our technique as a 
suitable biomarker for predicting the occurrence of severe exacerbations of COPD.  We 
hypothesized that pulmonary artery volumes will be associated with measurements of lung 
function and structure.  Furthermore, we hypothesized that pulmonary artery volumes will 
be able to predict the occurrence of COPD exacerbations. 
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CHAPTER 2: THREE-DIMENSIONAL SEGMENTATION OF 
PULMONARY ARTERY VOLUME FROM THORACIC COMPUTED 
TOMOGRAPHY IMAGING  
This chapter describes the development of a three-dimensional volumetric measurement 
for evaluating the size of the main, left and right pulmonary arteries as well as calculating 
total pulmonary artery volume. The reproducibility of the volumetric measurements is also 
reported in this chapter.  
 
The contents presented here has been adapted from work previously published in the SPIE 
Medical Imaging Conference Proceedings, Orlando, Florida, United States 2015, and is 
reproduced here with permission provided in Appendix B. 
TJ Lindenmaier, K Sheikh, E Bluemke, I Gyacskov, M Mura, C Licskai, L Mielniczuk, A 
Fenster, IA Cunningham and G Parraga, Three-Dimensional Segmentation of Pulmonary 
Artery Volume from Thoracic Computed Tomography Imaging. SPIE Medical Imaging, 
Renaissance Orlando at SeaWorld, Orlando, Florida, United States, February 21-26, 2015     
 Introduction 
Chronic obstructive pulmonary disease (COPD) affects the airways and the lung 
parenchyma.1  It is currently the fourth leading cause of death in the United States and is 
predicted to be the third leading cause of death worldwide by 2020.2  COPD is a 
heterogeneous disease with various clinical phenotypes, including chronic bronchitis, 
emphysema, asthma with fixed airflow obstruction, frequent exacerbation phenotype, and 
COPD associated with pulmonary hypertension.  There is an expanding body of literature 
seeking to define COPD phenotypes and identify predictive biomarkers.  The diagnosis of 
COPD is confirmed using spirometry measurements of the forced expiratory volume in 
one second (FEV1) and forced vital capacity (FVC).  While spirometry is a diagnostic 
prerequisite, it is insensitive to subclinical changes in lung function, correlates poorly with 
clinical symptoms including cardiovascular disease, is a poor predictor of mortality and 
does not accurately predict exacerbation frequency.3, 4  In addition to airflow limitation, 
COPD is also associated with cardiovascular disease and abnormalities of the pulmonary 
vasculature.  For example, COPD patients commonly develop pulmonary hypertension 
(PH) leading to increased morbidity and mortality.5  Previous work has shown that PH is 
associated with acute exacerbations of COPD and sudden worsening of symptoms resulting 
in hospitalization.6, 7  Patients with COPD frequently develop other cardiovascular 
abnormalities such as carotid atherosclerosis8-13, coronary artery calcification14-17 and 
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vascular dysfunction.7, 18-20  These findings cannot be explained by smoking history alone, 
further emphasizing the need for new biomarkers that can predict disease development and 
severity. 
Recent results from the Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) study21 suggested that a history of acute exacerbations of 
COPD was the single best predictor of future events.  This finding strengthens the need for 
biomarkers that can predict subclinical changes in lung function, disease development and 
severity.  Previous studies quantified the size of the pulmonary artery (PA) in order to 
evaluate pulmonary vasculature abnormalities as a potential predictor of COPD 
exacerbations.  Typically, the aorta (A) and pulmonary artery (PA) are quantified using 
manual diameter measurements at the level of the PA bifurcation in thoracic computed 
tomography (CT) images.7  It was recently shown in the COPDGene cohort (N=3464) that 
a PA/A ratio >1 was associated with acute exacerbations and the risk of future 
exacerbations.7  Moreover, a different study showed that an increase in PA diameter was 
associated with subclinical PH.22  Both of these studies utilized manual one-dimensional 
measurements of the pulmonary artery.  To enhance sensitivity and improve observer 
variability, we aimed to develop a three-dimensional (3D) measurement of the PA from 
thoracic CT.  We hypothesized that 3D volumetric measurements would have an intra-
observer variability <10% and high inter-observer agreement ICC > 0.90.  The 3D method 
is more time consuming and laborious and validation is required before a more automated 
approach is considered.  Therefore, our objective was to develop and test the 
reproducibility of 3D manual volumetric PA measurement from thoracic CT images. 
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 Methods 
2.2.1 Study Subjects 
All subjects provided written informed consent to a protocol that was approved by the local 
research ethics board (#15930) and Health Canada.  A total of 15 ex-smokers aged 56-79 
(mean age: 67±7 years) with a smoking history > 10 pack-years were randomly chosen 
from a cohort of 199 subjects.  Three subjects were randomly selected from each of the 
following four groups based on COPD disease severity using the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) classification: GOLD IV (FEV1 <30%), 
GOLD III (FEV1 30-49%), GOLD II (FEV1 50-79%), GOLD I (FEV1 ≥ 80%) and a fifth 
group without airflow limitation (FEV1/FVC ≥ 0.70). 
2.2.2 Imaging 
CT images were acquired on a 64-slice Lightspeed VCT scanner (General Electric Health 
Care, Milwaukee, WI USA) (64 × 0.625mm collimation, 120 kVp, 100 effective mA, tube 
rotation time = 500ms, pitch=1.0).23  Subjects were first coached through normal breathing.  
Once at functional residual capacity (FRC), subjects were instructed to inhale 1L of 
medical grade nitrogen gas (N2) from a Tedlar® bag (Jansen Inert Products, Coral Springs, 
FL, USA)23 to match lung volumes acquired using MRI. Imaging was performed using a 
spiral acquisition and reconstructed using a standard convolution kernel to 1.25mm.23  The 
effective dose for an average adult was estimated at 1.8mSv using the ImPACT CT patient 
dosimetry calculator based on the Health Protection Agency (UK) NRPB-SR250.24 
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2.2.3 PA Segmentation: Development and Application 
Reconstructed CT images were evaluated in Digital Imaging and Communications in 
Medicine (DICOM) format using custom-built software (3D Quantify V4.1.1, Robarts 
Research Institute, London, Canada) previously developed for carotid ultrasound 
measurements.25  The algorithm pipeline is summarized in Figure 2-1.   
 
Figure 2-1: PA Volume measurement algorithm pipeline. 
After setting the optimal window and level, such that the PA was well distinguished from 
the surrounding tissue, the observer navigated the CT volume, shown in the top left of 
Figure 2-2, to the plane where the bifurcation of the main pulmonary artery (MPA) into the 
left and right pulmonary arteries (LPA and RPA respectively) was clear, as shown in the 
middle left panel of Figure 2-2.   
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Figure 2-2: User input for PA measurement. The user first adjusted the window and 
level such that the PA was well distinguished from surroundings. The arterial bifurcation 
(BF) was identified and used as a landmark for manual placement of axes a1, a2, a3 from 
the BF that were parallel to the MPA, LPA and RPA respectively.  The cross sectional 
areas in planes perpendicular to each axis of segmentation were manually traced in 25 
slices for MPA and 20 slices for LPA and RPA (only 3 representative slices shown here) 
with inter-slice distance of 1.00 mm. The resulting volume was generated as shown in 
Equation 4. Voxels enclosed by each polygonal surface were extracted and their union was 
taken to account for the overlap between segmented vessels. The number of resulting 
voxels were then multiplied by the voxel dimensions to calculate TPAV. Bottom right 
panel shows a representative slice for the union of extracted voxels.  
 
The user then set the bifurcation point (BF), and manually identified the first axis (a1) of 
segmentation from the BF parallel to the MPA.  The cross-sectional area of the vessel was 
then manually segmented in 25 consecutive two-dimensional planes perpendicular to the 
axis of segmentation, starting at the BF, with an inter-slice distance (ISD) of 1.00 mm.  
This approach was repeated for the LPA and RPA (axes of segmentation a2 and a3 
respectively) for 20 consecutive perpendicular planes, starting from the BF.  Once the 
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vessels were traced, sub-volumes were generated by multiplying each area by half the ISD 
on either side of the segmented region, as shown in Figure 2-3, represented by dashed lines.   
 
Figure 2-3: PA volume generation. Sub-volumes were generated by multiplying the area 
of segmented contours by half the inter-slice distance (ISD) on either side of the contour, 
represented by dashed lines above. To generate volume measurements, sub-volumes were 
summed as shown in Equation 4. 
𝑉 =  
1
2
(𝐴1 + 𝐴𝑛) + ∑ 𝐴𝑖
𝑛−1
𝑖=2                                             (4) 
The general equation for calculating volumes in millimeters cubed is expressed as shown 
in Equation 4.  Volumes of the MPA, LPA and RPA were also obtained from generated 
polygonal surfaces in order to calculate a total PA volume (TPAV) for the pulmonary 
artery.  Polygonal surfaces were generated as previously described26 for segmentation of 
the carotid artery.  To generate TPAV, the union of voxels enclosed by each of the MPA, 
LPA and RPA was taken and multiplied by the voxel dimensions.  Taking the union of 
voxels, accounted for the overlap between polygonal surfaces.  Segmentation was 
performed by three observers.  Observer 1 (TJL) was a well-trained observer with previous 
experience in CT measurements of PA as well as carotid artery segmentation from 
ultrasound, while observers 2 (EB) and 3 (KS) received minimal training. 
2.2.4 Evaluation and Statistical Analysis 
Three observers evaluated MPA, LPA, RPA and TPA volumes for 15 ex-smokers.  
Measurements were repeated five times, and in random blinded fashion with 24 hr between 
measurements to reduce potential observer learning and bias.  To evaluate the intra-
observer variability, the coefficient of variation (CV) was generated (SD of five repeated, 
independent measurements divided by the mean) for each observer.  Inter-observer 
agreement was also evaluated using linear regression and intraclass correlation (ICC) 
analysis.  To test the long term reproducibility, observer 1 repeated measurements of the 
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same 15 subjects five times and intra-class correlation analysis was performed to assess 
agreement.  Observer 1 also performed diameter measurements of the MPA as previously 
described7 and the diameter mean over four consecutive center slices at the level of the 
bifurcation was used for this estimate.  IBM SPSS Statistics for Windows v21 (IBM Corp, 
Armonk, NY, USA 2012) and GraphPad Prism for Windows, v6.02 (GraphPad Software, 
La Jolla, CA, USA) was used for all analyses.  Results were considered significant when 
the probability of a type I error was less than 5% (p < .05). 
 Results and Discussion 
2.3.1 Relationship between PA volume and PA diameter 
Figure 2-4 shows the relationship for the MPA diameter and main pulmonary artery volume 
(MPAV) averaged from five rounds of measurements.  A second order polynomial was 
used to estimate the relationship between the gold standard diameter measurements and 
PA volumes and showed a strong association (r2=0.76) for PA diameter and volume.  Thus, 
our technique is in high agreement with the gold standard diameter measurement.  Three 
observers performed MPA, LPA, RPA and TPA volume measurements over five rounds 
of measurements, as previously mentioned, to evaluate inter- and intra-observer variability.  
 
Figure 2-4: Relationship between PA volume and diameter. Second order polynomial 
was used to evaluate the association between novel PA volume and diameter. 
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2.3.2 Intra-observer variability 
Figure 2-5 shows representative measurements of the same observer and different 
observers overlaid to visually asses the variability between measurements. Figure 2-6 
shows mean CV for each subject and observer.  The pooled CV for observer 1 was: 
MPA:2%, LPA:3%, RPA:2%, TPA:2%, for observer 2 was MPA:8%, LPA:5%, RPA:5%, 
TPA:6%, and for observer 3 was: MPA:3%, LPA:3%, RPA:3%, TPA:3 %.   
 
Figure 2-5: Representative measurements. Within and between observer agreements. 
Top panels show measurements performed by the same observer (observer 1) on two 
different subjects, high agreement on left and low agreement on right. Different colours 
represent measurements performed in two separate rounds of the trial. Bottom panels show 
measurements performed by three different observers (observer 1, observer 2 and observer 
3), on two different subjects, with high agreement on left and low agreement on right. Red 
outline was performed by observer 1 (well-trained), while blue and green outlines were 
performed by observers 2 and 3 respectively (minimal training). 
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Figure 2-6: Intra-observer variability. Mean CV for Observers 1-3. ID# 178, 196 were 
excluded from TPA measurements for Observer 2 – Round 4 due to missing data. 
 
2.3.3 Inter-observer variability 
Figure 2-7 shows strong linear relationships for mean MPA (r2=0.96, p<.001), LPA 
(r2=0.98, p<.001) RPA (r2=0.99, p<.001) and TPA (r2=0.98, p<.001) volumes from the five 
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rounds of measurements for observers 1 and 2 as well as strong linear relationships for 
mean MPA (r2=0.98, p<.001), LPA (r2=0.98, p<.001), RPA (r2=0.99, p<.001) and TPA 
(r2=0.99, p<.001) for observers 1 and 3. ICC analysis also showed high agreement for 
measurements performed by three observers (ICCMPA=0.98, ICCLPA=0.98, ICCRPA=0.99, 
ICCTPA=0.98). 
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Figure 2-7: Inter-observer variability. Linear relationships for mean MPA, LPA, RPA 
and TPAV measurements for observer 1 (expert) with observers 2 and 3 (minimally-
trained). 
 
2.3.4 Long-term variability 
To assess the long term reproducibility of our technique, observer 1 repeated five 
measurement rounds four months after completing the baseline reproducibility trial.  ICC 
analysis revealed high agreement for baseline and follow-up measurements 
(ICCMPA=0.998, ICCLPA=0.995, ICCRPA=0.998, ICCTPA=0.997). 
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 Conclusion 
We developed a manual method to generate three-dimensional volumes at the bifurcation 
for the main, left and right PA.  Volumetric measurements were in agreement (r2 = 0.76) 
with PA diameter measurements, which served as the gold standard.  Inter-observer 
variability was low with strong inter-observer correlations providing a strong rationale to 
automate this measurement for clinical workflows. 
 
 
 
 
 
 
 
 
 
 
  
45 
 
 
 
 References 
[1] Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease: GOLD executive summary. 
American journal of respiratory and critical care medicine 2007;176(6):532-55. 
[2] Raherison C,  Girodet P. Epidemiology of COPD. European Respiratory Review 
2009;18(114):213-21. 
[3] Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic 
obstructive pulmonary disease. Pulmonary pharmacology & therapeutics 
2006;19(3):189-99. 
[4] Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphysema and small airways in 
COPD. CHEST Journal 1996;109(2):353-9. 
[5] Chaouat A, Naeije R,  Weitzenblum E. Pulmonary hypertension in COPD. European 
Respiratory Journal 2008;32(5):1371-85. 
[6] Kirby M, Kanhere N, Etemad‐Rezai R, McCormack DG,  Parraga G. Hyperpolarized 
helium‐3 magnetic resonance imaging of chronic obstructive pulmonary disease 
exacerbation. Journal of Magnetic Resonance Imaging 2013;37(5):1223-7. 
[7] Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute 
exacerbations of COPD. New England Journal of Medicine 2012;367(10):913-21. 
[8] Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and 
emphysema: the MESA Lung Study. European Respiratory Journal 
2012;39(4):846-54. 
[9] Engström G, Hedblad B, Valind S,  Janzon L. Asymptomatic leg and carotid 
atherosclerosis in smokers is related to degree of ventilatory capacity: longitudinal 
and cross-sectional results from ‘Men born in 1914’, Sweden. Atherosclerosis 
2001;155(1):237-43. 
[10] Frantz S, Nihlén U, Dencker M, Engström G, Löfdahl CG,  Wollmer P. 
Atherosclerotic plaques in the internal carotid artery and associations with lung 
function assessed by different methods. Clinical physiology and functional imaging 
2012;32(2):120-5. 
[11] Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is 
associated with subclinical atherosclerosis. American journal of respiratory and 
critical care medicine 2009;179(1):35-40. 
[12] Lahousse L, van den Bouwhuijsen QJ, Loth DW, et al. Chronic obstructive pulmonary 
disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. 
American journal of respiratory and critical care medicine 2013;187(1):58-64. 
46 
 
 
 
[13] van Gestel YR, Flu W-J, van Kuijk J-P, et al. Association of COPD with carotid wall 
intima-media thickness in vascular surgery patients. Respiratory medicine 
2010;104(5):712-6. 
[14] Chae EJ, Seo JB, Oh Y-M, Lee JS, Jung Y,  Do Lee S. Severity of Systemic Calcified 
Atherosclerosis Is Associated With Airflow Limitation and Emphysema. Journal of 
computer assisted tomography 2013;37(5):743-9. 
[15] Dransfield MT, Huang F, Nath H, Singh SP, Bailey WC,  Washko GR. CT emphysema 
predicts thoracic aortic calcification in smokers with and without COPD. COPD: 
Journal of Chronic Obstructive Pulmonary Disease 2010;7(6):404-10. 
[16] McAllister DA, MacNee W, Duprez D, et al. Pulmonary function is associated with 
distal aortic calcium, not proximal aortic distensibility. MESA lung study. COPD: 
Journal of Chronic Obstructive Pulmonary Disease 2011;8(2):71-8. 
[17] Rasmussen T, Køber L, Pedersen JH, et al. Relationship between chronic obstructive 
pulmonary disease and subclinical coronary artery disease in long-term smokers. 
European Heart Journal–Cardiovascular Imaging 2013;14(12):1159-66. 
[18] Barr RG, Mesia-Vela S, Austin JH, et al. Impaired flow-mediated dilation is associated 
with low pulmonary function and emphysema in ex-smokers: the Emphysema and 
Cancer Action Project (EMCAP) Study. American journal of respiratory and 
critical care medicine 2007;176(12):1200-7. 
[19] Cinarka H, Kayhan S, Gumus A, et al. Arterial stiffness measured by carotid femoral 
pulse wave velocity is associated with disease severity in chronic obstructive 
pulmonary disease. Respiratory care 2013;59(2):274-80. 
[20] Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic 
obstructive pulmonary disease. American journal of respiratory and critical care 
medicine 2007;175(12):1259-65. 
[21] Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic 
obstructive pulmonary disease. New England Journal of Medicine 
2010;363(12):1128-38. 
[22] Lange TJ, Dornia C, Stiefel J, et al. Increased pulmonary artery diameter on chest 
computed tomography can predict borderline pulmonary hypertension. Pulm Circ 
2013;3(2):363-8. 
[23] Kirby M, Owrangi A, Svenningsen S, et al. On the role of abnormal DLCO in ex-
smokers without airflow limitation: symptoms, exercise capacity and 
hyperpolarised helium-3 MRI. Thorax 2013;68(8):752-9. 
[24] Shrimpton P,  Jones D. Normalised organ doses for x ray computed tomography 
calculated using Monte Carlo techniques and a mathematical anthropomorphic 
phantom. Radiation Protection Dosimetry 1993;49(1-3):241-3. 
47 
 
 
 
[25] Ainsworth CD, Blake CC, Tamayo A, Beletsky V, Fenster A,  Spence JD. 3D 
Ultrasound Measurement of Change in Carotid Plaque Volume A Tool for Rapid 
Evaluation of New Therapies. Stroke; a journal of cerebral circulation 
2005;36(9):1904-9. 
[26] Chiu B, Egger M, Spence JD, Parraga G,  Fenster A. Quantification of carotid vessel 
atherosclerosis. In: International Society for Optics and Photonics, 2006: 61430B-
B 
 
 
  
48 
 
 
 
CHAPTER 3: PULMONARY ARTERY ABNORMALITIES IN EX-
SMOKERS WITH AND WITHOUT AIRFLOW LIMITATION 
This chapter describes the relationship between pulmonary artery volume measurements, 
described in Chapter 2, and measurements of lung function and structure in a group of 
COPD ex-smokers and a small group of never-smokers. 
The contents of this chapter are to be submitted to the Journal of Chronic Obstructive 
Pulmonary Disease for peer review, April 2015.  
Tamas J Lindenmaier, Miranda Kirby, Gregory Paulin, Marco Mura, Christopher Licskai, 
Harvey O Coxson, Ian A Cunningham and Grace Parraga, Pulmonary Artery 
Abnormalities in Ex-smokers with and without Airflow Limitation, J COPD.  
 Introduction 
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the 
United States and estimates predict that in 2020, COPD will be the third leading cause of 
death worldwide.1  In COPD patients, chronic lung inflammation and tissue destruction is 
the result of  long-term inhalation of toxins, mainly tobacco smoke2, leading to the 
accelerated loss of lung function3, reduced quality-of-life, and premature death.4  As the 
disease progresses, those with moderate-to-severe disease are likely to experience acute 
events known as exacerbations.5  These individuals experience a reduced quality of life 
and seek immediate medical attention which often results in hospitalization, placing a large 
burden on the healthcare system.  
Although the hallmark feature of COPD is pulmonary airflow limitation measured using 
spirometry, COPD is also associated with vascular abnormalities including coronary 
vascular and cerebrovascular disease6-9 and pulmonary artery abnormalities.3  Importantly, 
vascular disease is the single largest cause of hospitalization in COPD patients with mild 
or moderate disease and after lung cancer, the leading cause of death.10, 11  There is also a 
dose-response relationship for pulmonary structure-function abnormalities with carotid 
atherosclerosis12-17, coronary artery calcification6-9 and vascular dysfunction.3, 18-20  While 
this previous work showed the importance of vascular disease in COPD patients that cannot 
be explained by smoking history alone12, 13, 15-17, 21, the mechanisms of vascular disease 
acceleration in COPD patients are not well-established.   
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We recently showed that ex-smokers with normal airflow measurements reported 
significantly greater ventilation abnormalities, measured using hyperpolarized noble gas 
magnetic resonance imaging (MRI), and more severe carotid atherosclerosis as compared 
to never-smokers.22  This study exploited the sensitivity of three-dimensional (3D) 
pulmonary MRI and carotid ultrasound and provided quantitative evidence of mild airways 
disease and carotid plaque that was significantly greater in ex-smokers as compared to 
never-smokers.  Based on these previous findings, we sought to ascertain whether there 
were also pulmonary artery abnormalities in otherwise normal ex-smokers without airflow 
limitation.  This is important because there is a dearth of direct evidence relating subclinical 
pulmonary disease (airways disease and emphysema) with pulmonary artery abnormalities 
in otherwise healthy ex-smokers.  We aimed therefore to quantify any potential underlying 
relationships between pulmonary airway and parenchymal abnormalities with pulmonary 
artery abnormalities in mild and subclinical COPD.  We also aimed to quantitatively 
compare pulmonary artery morphology in normal ex- and healthy never-smokers as well 
as in COPD patients.  The relationship of pulmonary artery abnormalities3 and pulmonary 
hypertension23-25 with lung abnormalities in COPD is well-established.  In one recent 
example, the relationship of pulmonary artery abnormalities with acute exacerbations of 
COPD3 was shown, but the relevance of this for clinical practice was not ascertained.  This 
was an important results because until now there are very few quantitative biomarkers 
available that help predict COPD exacerbations.3, 26 
Here our objective was to measure three-dimensional pulmonary artery vessel 
measurements from thoracic CT as well as pulmonary airways disease and emphysema 
measurements from thoracic CT and MRI in a small group of ex-smokers and a control 
group of healthy never-smokers.  In the subset of patients with COPD and based on 
previous findings that related 1D pulmonary artery measurements and exacerbations in the 
large-scale ECLIPSE and COPDgene cohorts, we also aimed to determine the sensitivity 
of 3D pulmonary artery measurements to COPD exacerbations.  We hypothesized that 
quantitative 3D imaging measurements of the pulmonary artery, airways and parenchyma 
would reveal the direct relationships of early or subclinical pulmonary disease with 
pulmonary artery abnormalities in ex-smokers.  
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 Methods 
3.2.1 Study Participants 
All research volunteers provided written informed consent to a protocol, approved by a 
local research ethics board and Health Canada.  We conducted retrospective analysis of a 
group of ex-smokers with or without airflow limitation and healthy never-smoker subjects 
which served as the control group.  The inclusion criteria for COPD ex-smokers included 
smoking history ≥10 pack-years, 50-85 years of age with a physician diagnosis of COPD 
and post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity 
(FVC) ratio <0.70, in accordance with the Global initiative for chronic Obstructive Lung 
Disease (GOLD) criteria.27  Ex-smokers without airflow limitation were enrolled with the 
same age-range and smoking history but with FEV1/FVC ≥0.70.  Exclusion criteria 
included a current diagnosis of asthma or other respiratory conditions.  We did not 
prospectively exclude subjects with other COPD co-morbidities. The inclusion criteria for 
the healthy never-smokers was 60 to 90 years of age with a smoking history of <0.5 pack-
years and no history of unstable cardiovascular disease or chronic respiratory disease.  
Because of the significant impact of exacerbations on COPD patient mortality28, we 
recorded severe exacerbations requiring hospitalization for all patients with COPD.  The 
number of acute exacerbations requiring hospitalization was determined using patient 
hospital records (PowerChart® Cerner Corporation, Missouri, USA) as previously 
described.29  The total number of hospitalizations was defined as the total number of 
hospitalizations that occurred between 2.5yr prior to and 2.5yr following the study visit 
(from time -2.5 to 2.5 years).  The number of prior hospitalizations was defined as the total 
number of hospitalizations between 2.5yr and 5yr prior to the study visit (from time -5  
to -2.5 years).  
3.2.2 Spirometry, plethysmography, quality of life and exercise 
capacity measurements 
Spirometry and lung volumes were acquired using body plethysmography (MedGraphics 
Corporation, St Paul, Minnesota, USA) following American Thoracic Society and 
European Respiratory Society (ERS) guidelines;30 the attached gas analyzer 
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(MedGraphics) was used to measure the diffusing capacity for carbon monoxide (DLCO).  
Quality of life was assessed using the St. George’s Respiratory Questionnaire  
(SGRQ)31, 32; exercise capacity was measured using a standard 6-Minute Walk Distance 
Test (6MWD)33.   
3.2.3 Image acquisition 
MRI was performed using a 3.0 Tesla MR750 (General Electric Health Care, Milwaukee, 
WI) system34 for acquisition of conventional 1H, 3He static ventilation and 3He diffusion-
weighted MRI.  Conventional 1H MRI was acquired during 1.0L breath-hold of N2 from a 
1.0 L Tedlar® bag from functional residual capacity (FRC).  Prior to 3He static ventilation 
and 3He diffusion-weighted MRI, a spin-exchange polarizer system (Polarean, Durham, 
NC, USA) was used to polarize 3He gas to 30-40%.  3He static ventilation and diffusion-
weighted imaging were performed following inhalation of a 3He/N2 gas mixture (
3He dose 
= 5 ml/kg body weight) from a 1.0 L Tedlar® bag from FRC as previously described.34 
Multi-detector CT was performed using the 64-slice Lightspeed VCT system (GEHC, 
Milwaukee, WI USA) with participants in breath-hold after inhalation of 1.0L of N2 from 
FRC35 in order to match the MRI lung volume.  The ECLIPSE imaging protocol36 was 
adapted and used: 64x0.625mm collimation, 120kVp, 100 effective mA, 500ms tube 
rotation time, pitch of 1.00 and image reconstruction using a standard convolution kernel 
to 1.25mm.   We calculated radiation dose according to our manufacturer settings using the 
ImPACT CT patient dosimetry calculator based on the Health Protection Agency (UK) 
NRPB-SR250 and the total effective dose for an average adult was 1.8 mSv.37 
3.2.4 Image analysis 
All MRI and CT analyses were performed by an expert in quantitative imaging analysis 
(M.K) with five years of experience developing and performing semi-automated 3He MRI 
segmentation using custom-built software generated using MATLAB R2007b (The Math-
works Inc., Massachusetts, USA).  The inter- and intra-reproducibility of the 3He MRI 
segmentation software was previously evaluated in subjects with COPD38 and therefore 
MR images were evaluated once by a single expert observer.  3He MRI ventilation defect 
percent (VDP) was quantified by registering the 3He static ventilation images to the 1H MR 
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images in order to delineate the defect boundary as previously described.39  3He apparent 
diffusion coefficient (ADC) maps were also generated from 3He diffusion-weighted images 
as previously described.40   
Pulmonary CT measurements were generated using Pulmonary Workstation 2.0 (VIDA 
Diagnostics, Inc., Coralville, IA) including airway wall area (WA) and lumen area (LA) 
for 5th generation airways41, the relative area of the CT density histogram with attenuation 
values < −950 HU (RA950)42, and low attenuation clusters (LAC) of connected regions with 
CT densitometry values < -950 HU.43  
For volumetric analysis of the pulmonary arteries, DICOM (Digital Imaging and 
Communications in Medicine) thoracic CT images were evaluated using custom-built 
software (3D Quantify V4.1.1, Robarts Research Institute, London, Canada), originally 
developed for three-dimensional visualization and quantification of carotid ultrasound 
volumes.44  The main pulmonary artery volume, left pulmonary artery volume and right 
pulmonary artery volume were generated, as previously described.45  As shown in Figure 
3-1, the bifurcation of the main pulmonary artery was identified as the branch-point 
between the left and right pulmonary arteries.  As previously described45, the axes of 
segmentation were established from the bifurcation (BF) parallel to each of the main, left 
and right pulmonary arteries.  The artery wall boundary was manually segmented in planes 
perpendicular to the axes of segmentation for 25 x 1mm slices for the main and 20 x 1mm 
slices for the left and right pulmonary arteries.  Based on the segmented areas and the inter-
slice distance, a volume for the segmented region of the vessel was generated.  Total 
pulmonary artery volume was also generated as previously described.45  To account for 
overlapping regions between main, left and right pulmonary artery volume measurements, 
the union of voxels enclosed by each boundary was taken and multiplied by the voxel 
dimensions. We previously reported low inter- and intra-observer variability for pulmonary 
artery volumetric measurements and therefore measurements were performed by a single 
observer (T.J.L).45  To account for gender differences in pulmonary artery volumes, 
measurements were normalized by body surface area and age.   
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It was previously shown that the pulmonary artery to aorta diameter ratio was associated 
with a history of COPD exacerbations and future exacerbations.3 Therefore, we measured 
the main pulmonary artery and aorta diameters as previously described3, averaged from 
four consecutive centre CT slices where the bifurcation was visible.  
 
 
Figure 3-1: PA volume measurements methodology. Left panel depicts CT volume and 
the level of the bifurcation (BF) where the axes of segmentation are defined from the BF 
parallel to each of the MPA, LPA and RPA. The middle panel outlines a representative 
slice of the segmented artery. In the right panel the segmented MPA, LPA and RPA are 
shown.  
 
3.2.5 Statistical Analysis 
We used IBM SPSS Statistics for Windows v21 (IBM Corp, Armonk, NY, USA 2012) and 
GraphPad Prism for Windows, v6.02 (GraphPad Software, La Jolla, CA, USA) for 
statistical analyses.  A one-way analysis of variance (ANOVA) with post-hoc Tukey HSD 
(Honest Significant Differences) was conducted to evaluate differences between groups.  
Pearson correlations were determined for pulmonary artery volumes and pulmonary 
function measurements. We also performed univariate correlations for the total number of 
severe exacerbations with all clinical, physiological and imaging measurements.  A 
multivariate zero-inflated Poisson model was used to evaluate the relationship between the 
total number of severe exacerbations with physiological and imaging measurements using 
the PROC COUNTREG procedure in SAS 9.2 software (SAS Institute, Cary, NC).  All 
measurements with significant univariate correlations were included in the multivariate 
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model.  A zero-inflated Poisson model46 was used because the total number of 
hospitalizations included a large proportion of zeroes.  From the significant multivariate 
model, we reported the fold-change in total exacerbations which was defined as the 
regression coefficient divided by the standard error. Cox regressions were conducted to 
determine hazard ratios for the occurrence of first exacerbation post visit.  Results were 
considered significant when the probability of a type I error was less than 5% (p < .05). 
 Results 
3.3.1 Subject Characteristics 
Table 3-1 shows the demographic characteristics for the study population which was a 
convenience sample of 35 never-smokers (71±7y) and 124 ex-smokers including 68 ex-
smokers with airflow limitation (71± 9y) and 56 ex-smokers without airflow limitation (69 
±10y).  One-way analysis of variance (ANOVA) showed significant differences between 
the three subgroups for most parameters but not for age (p=.3) or 6MWD (p=.06).  For the 
two ex-smoker subgroups, there were significant differences for FEV1%pred (p<.001), 
FEV1/FVC (p<.001), FRC%pred (p<.001), TLC%pred (p<.001), DLCO%pred (p<.001), VDP 
(p<.001), ADC (p<.001), RA950 (p<.001), airway count (p<.001), and the main (p=.014), 
right (p=.001) and total (p=.003) pulmonary artery volume.  
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Table 3-1 Subject Characteristics 
 Never-Smokers 
(n=35) 
Mean (±SD) 
FEV1/FVC ≥ 70% 
(n=56) 
Mean (±SD) 
FEV1/FVC < 70% 
(n=68) 
Mean (±SD) 
Sig. 
Diff. 
p 
Age yrs 71 (7) 69 (10) 71 (9) .29 
BMI kg/m2 26 (3) 29 (4) 27 (4) <.001 
Pack years - 28 (17) 47 (29) <.001 
FEV1 %pred 107 (18) 98 (17) 63 (23) <.001 
FEV1/FVC % 77 (6) 80 (6) 50 (13) <.001 
FRC %pred 104 (22) 95 (19) 139 (36) <.001 
TLC %pred 100 (14) 101 (12) 118 (18) <.001 
DLCO %pred 91 (16) 79 (20) 54 (19) <.001 
SGRQ - 25 (21) 40 (17) <.001 
6MWD m - 401 (96) 369 (90) .06 
3He MRI VDP % 3 (2) 6 (3) 18 (10) <.001 
3He MRI ADC cm2/s 0.29 (0.03) 0.28 (0.04) 0.42 (0.11) <.001 
CT RA950 % 1 (1) 1 (1) 11 (11) <.001 
WA% 67 (2) 65 (2) 65 (2) .001 
Airway count 132 (40) 109 (38) 78 (29) <.001 
Main PA Volume cm3 21 (4) 24 (3) 25 (4) <.001 
Left PA Volume cm3 8 (1) 9 (1) 10 (1) <.001 
Right PA Volume cm3 8 (1) 9 (1) 10 (2) <.001 
Total PA Volume cm3 28 (4) 31 (3) 33 (5) <.001 
BMI =  Body Mass Index; FEV1 = Forced Expiratory Volume in 1 Second; %pred = Percent 
Predicted; FVC = Forced Vital Capacity; FRC = Functional Residual Capacity; TLC = Total Lung 
Capacity; RV = Residual Volume; DLCO = Diffusing Capacity for Carbon Monoxide; 6MWD = 
Six Minute Walk Distance; VDP = Ventilation Defect Percent; ADC = Apparent Diffusion 
Coefficient; RA950 = CT attenuation values below -950 HU; WA% = Wall Area Percent; PA = 
Pulmonary Artery; SD = Standard Deviation; Sig. Diff. = significant difference between ex-
smokers with and without airflow limitation and never-smokers. Main, left, right and total PA 
volumes adjusted for body surface area and age. 
 
 
3.3.2 Imaging Measurements 
 
Figure 3-2 shows qualitative results including hyperpolarized 3He MRI static ventilation 
images, ADC maps, CT airway trees as well as pulmonary artery segmentations for four 
representative subjects.  Subject 1 is a 76y male ex-smoker with grade II COPD, significant 
emphysema and ventilation defects and visibly enlarged main, left, right and total 
pulmonary volume.  Subject 2 is an 86y male ex-smoker with GOLD grade III COPD, 
significant emphysema and ventilation defects and significantly enlarged main, left, right 
and total pulmonary artery volume.   
 
56 
 
 
 
 
Figure 3-2: Representative subject measurements 
Subject 1 is a 76y male ex-smoker with GOLD grade II COPD and FEV1/FVC=39%, 
FEV1%pred=56%, VDP=24%, ADC=0.50cm
2/s, WA%=66%, main pulmonary artery 
volume=29cm3, left pulmonary artery volume =11cm3, right pulmonary artery volume 
=11cm3 and total pulmonary artery volume=38cm3; Subject 2 is a 86y male ex-smoker with 
GOLD grade III COPD and FEV1/FVC = 35%, FEV1%pred = 38%, VDP =30%, ADC= 
0.48cm2/s, WA% = 67%, main pulmonary artery volume =30cm3, left pulmonary artery 
volume= 11cm3, right pulmonary artery volume = 12cm3 and total pulmonary artery 
volume = 40cm3; Subject 3 is a 67y male ex-smoker FEV1/FVC=94%, FEV1%pred =103%, 
VDP= 5%, ADC = 0.30cm2/s, WA% = 56%, main pulmonary artery volume =24cm3, left 
pulmonary artery volume = 9cm3, right pulmonary artery volume =9cm3 and total 
pulmonary artery volume=31cm3; Subject 4 is a 73y male never-smoker FEV1/FVC=76%, 
FEV1%pred=122%, VDP= 2%, ADC = 0.34cm
2/s, WA%=66%, main pulmonary artery 
volume=20cm3, left pulmonary artery volume =8cm3, right pulmonary artery volume 
=8cm3 and total pulmonary artery volume =28cm3. Scale bars=1cm. 
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In contrast, Subject 3 is a 67y male ex-smoker with normal airflow measurements 
(FEV1/FVC= 94%, FEV1%pred=103%) and few ventilation abnormalities concomitant with 
mild emphysema (VDP=5%, ADC=0.30cm2/s) and with modest main (24 cm3), left 
(9cm3), right (9cm3) and total pulmonary artery volume (31 cm3).  Finally, subject 4 is a 
73y male never-smoker with normal airflow, no ventilation abnormalities or emphysema, 
and visibly smaller main (20cm3), left (8cm3), right (8cm3) and total pulmonary artery 
volume (28cm3).  Figure 3-2 shows that subjects 1 and 2 have visibly obvious ventilation 
defects while for subjects 3 and 4 there is homogeneous ventilation throughout the lung.  
In a similar fashion, ADC maps indicated greater emphysematous destruction in subjects 
1 and 2 as compared to subjects 3 and 4.  Furthermore, subjects 3 and 4 appear to report 
more complete airway trees, while subjects 1 and 2, presented with truncated airway trees 
that was coincident with greater pulmonary artery volumes for subjects 1 and 2 as 
compared to subjects 3 and 4.  
 
Figure 3-3 and Table 3-1 show quantitative measurements and the significant differences 
in pulmonary artery volumes between ex- and never-smokers.  As shown in Figure 3-3, 
there were significantly greater main, left, right and total pulmonary artery volumes in ex-
smokers with and without airflow limitation as compared to never-smokers (p<.01).  In 
addition, ex-smokers with airflow limitation presented with greater main, right and total 
pulmonary artery volumes compared to ex-smokers without airflow limitation (p=.01).   
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Figure 3-3: PA Volume Differences between Ex-smokers and Never-Smokers. Post-
hoc analysis revealed significant differences between ex- and never- smokers for all PA 
volumes. Significant differences in pulmonary artery volume were also observed between 
ex-smokers with and without airflow limitation except for the left pulmonary artery. 
3.3.3 Relationships 
Table 3-2 shows Pearson Correlations for pulmonary artery volumes with measurements 
of emphysema, airways disease and airflow limitation for healthy never-smokers and all 
ex-smokers by subgroup.  For all subjects, there were significant correlations for 
FEV1/FVC, FEV1%pred, DLCO%pred, airway count, VDP and ADC with main, left, right and 
total pulmonary artery volume.  For all ex-smokers, VDP was significantly correlated with 
main (r=0.23, p=.009), left (r=0.20, p=.028), right (r=0.27, p=.003) and total (r=0.25, 
p=.005) pulmonary artery volume and FEV1/FVC with right pulmonary artery volume  
(r=-0.19, p=.03).  For ex-smokers with airflow limitation, there were no significant 
correlations but in ex-smokers without airflow limitation, there were significant 
correlations for main (r = 0.28, p = .037), right (r = 0.38, p = .004) and total (r = 0.32, p = 
.016) pulmonary artery volume with ADC only.  For never- smokers, there were 
numerous significant correlations including for FEV1%pred with main pulmonary artery 
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volume   
(r=-0.37, p=.03), for FEV1/FVC with main (r=-0.36, p=.04), left (r=-0.40, p=.02), right  
(r=-0.39, p=.02) and total (r=-0.39, p=.02) pulmonary artery volume, for airway count with 
main pulmonary artery volume (r=-0.38, p=.026), for VDP with main (r=0.45, p=.007), left 
(r=.045, p=006), right (r=0.46, p=.006) and total (r=0.46, p=.006) pulmonary artery 
volume, and for ADC with left (r=0.35, p=.04), right (r=0.34, p=.045), and total (r=0.34, 
p=.047) pulmonary artery volume. 
 
Table 3-2 Pearson correlations for pulmonary artery volumes 
Parameter MPAV r (p) LPAV r (p) RPAV r (p) TPAV r (p) 
All Subjects (n=159) 
FEV1/FVC % -0.26 (<.001) -0.23 (.003) -0.30 (<.001) -0.28 (<.001) 
FEV1 %pred -0.24 (.002) -0.22 (.007) -0.23 (.004) -0.21 (.007) 
DLCO %pred -0.22 (.006) -0.21 (.009) -0.26 (.001) -0.24 (.002) 
Airway count -0.31 (<.001) -0.28 (<.001) -0.27 (.001) -0.26 (.001) 
RA950 % 0.14 (.08) 0.15 (.07) 0.17 (.031) 0.16 (.042) 
VDP % 0.37 (<.001) 0.35 (<.001) 0.38 (<.001) 0.37 (<.001) 
ADC cm2/s 0.21 (.008) 0.20 (.012) 0.24 (.002) 0.23  (.003) 
All Ex-smokers (n=124) 
FEV1/FVC % -0.14 (.12) -0.09 (.33) -0.19 (.03) -0.17 (.06) 
FEV1 %pred -0.02 (.82) 0.003 (.97) -0.05 (.58) -0.04 (.69) 
DLCO %pred -0.06 (.53) -0.01 (.95) -0.13 (.15) -0.11 (.25) 
Airway count -0.09 (.31) -0.08 (.37) -0.10 (.29) -0.09 (.30) 
RA950 % 0.03 (.73) 0.03(.77) 0.08 (.35) 0.07 (.43) 
VDP % 0.23 (.009) 0.20 (.028) 0.27 (.003) 0.25 (.005) 
ADC cm2/s 0.11 (.24) 0.08(.38) 0.16 (.081) 0.14 (.12) 
 Ex-smokers FEV1/FVC < 70% (n=68)  
FEV1/FVC % 0.18 (.13) 0.18 (.15) 0.17 (.16) 0.17 (.16) 
FEV1 %pred 0.23 (.05) 0.24 (.05) 0.24 (.05) 0.24 (.05) 
DLCO %pred 0.14 (.26) 0.11 (.36) 0.09 (.45) 0.10 (.43) 
Airway count 0.08 (.50) 0.09 (.46) 0.10 (.43) 0.10 (.44) 
RA950 % -0.16 (.20) -0.13 (.28) -0.12 (.34) -0.12 (.33) 
VDP % 0.09 (.47) 0.09 (.46) 0.09 (.46) 0.09 (.46) 
ADC cm2/s -0.15 (.23) -0.13 (.29) -0.12 (.34) -0.12 (.33) 
 Ex-smokers FEV1/FVC ≥ 70% (n=56)  
FEV1/FVC % -0.07 (.59) 0.02 (.90) -0.17 (.21) -0.11 (.41) 
FEV1 %pred 0.10 (.45) 0.07 (.60) 0.13 (.34) 0.12 (.40) 
DLCO %pred 0.03 (.84) 0.12 (.39) -0.07 (.61) -0.01 (.94) 
Airway count -0.07 (.60) -0.09 (.53) -0.05 (.69) -0.07 (.63) 
RA950 % 0.23 (.09) 0.17 (.22) 0.28 (.04) 0.25 (.07) 
VDP % 0.23 (.09) 0.22 (.10) 0.22 (.11) 0.23 (.10) 
ADC cm2/s 0.28 (.037) 0.17 (.21) 0.38 (.004) 0.32 (.016) 
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FEV1 = Forced Expiratory Volume in 1 Second; DLCO = Diffusing Capacity for Carbon 
Monoxide; RA950 = CT attenuation < -950 HU; VDP = Ventilation Defect Percent; ADC = 
Apparent Diffusion Coefficient; MPAV = Main Pulmonary Artery Volume; LPAV = Left 
Pulmonary Artery Volume; RPAV = Right Pulmonary Artery Volume; TPAV = Total Pulmonary 
Artery Volume.    
 
In the 68 COPD ex-smokers, there were four previous exacerbations in the 2.5 year period 
between 5 and 2.5 years prior to the imaging visit and 46 total exacerbations in the 5 year 
period between 2.5 years prior to 2.5 years post visit.  Table 3-3 shows the result of a 
multivariate model for predicting the total number of exacerbations in these 68 patients.  
Since there were no univariate correlations for age, body surface area, RA950, WA%, 
3He 
MRI ADC, pulmonary artery/aorta diameter ratio, main pulmonary artery volume, and 
right pulmonary artery volume with total exacerbations, they were not included in the 
multivariate model.  As shown in Table 3-3, FEV1%pred was significantly (p=.004) 
associated with the total number of exacerbations with a three-fold increase in the number 
of total exacerbations predicted by a decrease of 1%predicted in FEV1.  In addition, DLCO 
was also significantly associated (p=.03) with exacerbations; a two-fold increase in total 
exacerbations was predicted by an increase in DLCO of 1%predicted.  Exercise capacity 
(6MWD) was significantly (p=.04) associated with exacerbations; a two-fold increase in 
total exacerbations was related to a one meter decrease in the distance walked.  Finally, 
total pulmonary artery volume was significantly (p=.03) associated with the total number 
of exacerbations; for every 1cm3 increase in total pulmonary artery volume, a two-fold 
increase in total exacerbations was predicted.   
 
 
  
     
     
 
Never-Smokers (n=35) 
FEV1/FVC % -0.36 (.035) -0.40 (.019) -0.39 (.020) -0.39 (.020) 
FEV1 %pred -0.37 (.030) -0.25 (.15) -0.27 (.12) -0.27 (.11) 
DLCO %pred 0.06 (.75) -0.05 (.80) -0.03 (.87) -0.03 (.89) 
Airway count -0.38 (.026) -0.24 (.16) -0.26 (.12) -0.27 (.11) 
RA950 % -0.12 (.49) 0.00 (.98) -0.02 (.90) -0.03 (.87) 
VDP % 0.45 (.007) 0.45 (.006) 0.46 (.006) 0.46 (.006) 
ADC cm2/s 0.28 (.10) 0.35 (.039) 0.34 (.045) 0.34 (.047) 
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Table 3-3 Relationships with total exacerbations in COPD (n=68) 
BSA = Body Surface Area; FEV1 = Forced Expiratory Volume in 1 Second; DLCO = Diffusing 
Capacity for Carbon Monoxide; RV = Residual Volume; TLC = Total Lung Capacity; SGRQ = St. 
George’s Respiratory Questionnaire; 6MWD = Six Minute Walk Distance; RA950 = CT attenuation 
values below -950 HU; WA% = Wall Area Percent of 5th generation airways; VDP = Ventilation 
Defect Percent; ADC = Apparent Diffusion Coefficient; PA = Pulmonary Artery, A = Aorta;  
 
 
 Discussion 
Our objective was to evaluate three-dimensional measurements of the pulmonary artery 
derived from thoracic CT45 in a relatively small group of 159 never-smokers and ex-
smokers with and without COPD.  We observed: 1) pulmonary artery volumes were 
significantly greater in ex-smokers compared to never-smokers, and significantly greater 
in ex-smokers with airflow limitation as compared to ex-smokers with normal lung 
function, 2) pulmonary artery volumes were associated with pulmonary structure and 
function measurements when all subjects were grouped together, and, 3) a small change of 
Parameter (+/- SD) Relationships With Total Exacerbations 
(2.5 yrs prior to 2.5 yrs post visit) 
Univariate 
r (p) 
Multivariate Model 
Fold Change p 
Age yrs 0.15 (.23) - - 
BSA m2 -0.07 (.58) - - 
Previous Exacerbations (5 to 2.5 yrs prior visit)  0.64 (<.001) 1.75 .08 
FEV1 %pred -0.38 (.002) -2.88 .004 
DLCO %pred -0.26 (.034) 2.12 .03 
RV/TLC %pred 0.31 (.011) -0.87 .38 
SGRQ Score 0.36 (.003) 0.05 .96 
6MWD m -0.36 (.003) -2.08 .04 
CT RA950 % 0.19 (.12) - - 
WA% 0.10 (.42) - - 
Airway Count  -0.36 (.002) -1.26 .21 
3He MRI VDP % 0.32 (.008) 0.73 .46 
3He MRI ADC cm2/s 0.14 (.25) - - 
PA/A diameter  0.11 (.37) - - 
Main PA Volume cm3 0.22 (.07) - - 
Left PA Volume cm3 0.33 (.005) -0.24 .81 
Right PA Volume cm3 0.24 (.051) - - 
Total PA Volume cm3 0.25 (.037) 2.12 .03 
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1cm3 in total pulmonary artery volume predicted a 2-fold change in the number of 
exacerbations in 68 COPD patients.  
First, we evaluated differences in pulmonary artery volumes for never-smokers and ex-
smokers with and without airflow limitation.  We observed significantly greater pulmonary 
artery volumes for ex-smokers with airflow limitation as compared to ex-smokers without 
airflow limitation.  This is important because previous research25 showed that pulmonary 
artery size is associated with pulmonary hypertension, a relatively common finding in 
COPD patients and concomitant with increased morbidity and mortality25, 47 in these 
patients.  Furthermore, we observed significantly greater pulmonary artery volumes for ex-
smokers without airflow limitation as compared to never-smokers. This finding suggests 
that the pulmonary arteries are abnormally enlarged even in ex-smokers without 
obstruction.  These results demonstrate that early or mild pulmonary abnormalities may be 
present even at early stages of the disease, which may play an important role in predicting 
patient outcomes. 
We evaluated the relationship of the main, left, right and total pulmonary artery volume 
with FEV1%pred, FEV1/FVC, DLCO%pred, as well as CT and MRI airway and emphysema 
measurements.  It is interesting to note that when we grouped all ex- and never-smokers 
together, we observed modest correlations between pulmonary artery volumes and 
measurements of lung function and structure.  We also expected to observe these trends 
when analyzing ex-smokers with airflow limitation alone, as previous work demonstrated 
that individuals with a greater pulmonary artery to aorta diameter ratio had significantly 
declined lung function.3  However, when analyzing ex-smokers with airflow limitation 
alone, we did not observe significant correlations between pulmonary artery volumes and 
lung function-structure measurements, suggesting that pulmonary artery enlargement may 
have developed secondary to COPD in our subject group.  
We also explored the relationship between pulmonary artery volumes and exacerbations of 
COPD. In the resultant significant model that explained total COPD exacerbations in 68 
ex-smokers with airflow limitation, previous exacerbations were not a significant predictor, 
which was surprising in light of previous work.26  However, the number of previous 
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exacerbations was likely not a predictor of total exacerbations as only a single subject 
experienced 4 previous exacerbations (between 5 years and 2.5 years prior to study).  
Consistent with previous work that showed the association between 6MWD and COPD 
hospitalization48,  we observed that the 6MWD was a significant predictor in our 
multivariate model and reported that a 1m decrease in 6MWD resulted in a two-fold 
increase in total exacerbations.  While in our study, FEV1%pred was associated with a 3-
fold increase in total exacerbations, previous studies showed that FEV1 correlated weakly 
with clinical symptoms including cardiovascular disease and exacerbation frequency.49, 50  
Total pulmonary artery volume was significantly (p=.03) associated with exacerbations 
while the PA:A ratio which was associated with acute exacerbations of COPD in the 
COPDGene (n = 3464) and ECLIPSE (n = 2005) studies3 was not significant in our model.  
This suggests that the three-dimensional total pulmonary artery volume measurement may 
have a stronger association with COPD exacerbations than the PA:A ratio. 
It is important to address the limitations that we encountered throughout this work.  First, 
we must acknowledge that subject groups consisted of a relatively small sample size as 
compared to previous studies using the one-dimensional measurement.3  Our study was 
limited to and only included those exacerbations that required hospitalizations.  Based on 
a previous study, about 50% of exacerbations go unreported5 and such events should be 
considered in future studies as they may provide additional information when predicting 
future exacerbations.  Several studies have shown the relationship between pulmonary 
artery size and pulmonary hypertension23-25, 51-54.  It has also been shown that individuals 
with pulmonary hypertension have an increased risk of experiencing a COPD 
exacerbation.48  While we sought to explore the relationship between pulmonary artery 
enlargement and COPD, it may be of importance to also include pulmonary artery pressure 
measurements in future analyses.  Unfortunately, right-heart catheterization data was not 
acquired for this group of patients and therefore pulmonary artery pressures could not be 
directly measured and included in our analyses. 
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In summary, we demonstrated that pulmonary artery volume changes may develop in very 
early or subclinical stages of COPD.  We also showed that total pulmonary artery volume 
predicted COPD exacerbations, in a relatively small number of COPD patients in whom 
there were very few previous exacerbations. 
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK 
 Summary 
COPD exacerbations are severe events that result in decreased health-related quality of life 
and contribute to increased morbidity and greater mortality rates.1, 2  Exacerbations are also 
of major impact on our healthcare system, as hospitalizations associated with treatment of 
these events are costly.3-5  It has been previously shown that the frequency of exacerbations 
increases with the severity of COPD and that this is an independent determinant of health-
related patient quality of life.1, 2  Biomarkers for predicting the occurrence of exacerbations 
have not been well established; however, numerous studies have outlined several risk 
factors, such as a decreased exercise capacity, that are associated with a higher 
exacerbation frequency.6-8  In particular, Hurst et al. demonstrated that, in a group of 2138 
subjects, the single best predictor of future exacerbations was the occurrence of previous 
exacerbations.  This was consistent in COPD patients across GOLD severity grades.7  A 
further study by Wells et al., which included 3464 subjects from the COPDGene study as 
well as 2005 individuals from the ECLIPSE study, showed that a pulmonary artery to aorta 
diameter ratio >1 was associated with a history of acute exacerbations.8  Furthermore, this 
ratio was associated with risk factors of future exacerbations.8  However, this study was 
limited in that it relied on a simple one-dimensional diameter measurement.  We believe 
that such a measurement is not sensitive to three-dimensional morphological changes of 
the pulmonary vasculature, as morphological changes could vary in different dimensions.  
A three-dimensional volumetric measurement approach would be more sensitive in 
quantifying changes in pulmonary artery size because it would account for morphological 
changes in all three Cartesian planes and would take into consideration a larger section of 
the vessel.  
Therefore, the objectives of this thesis were the following: 1) to develop a three-
dimensional technique for assessing the size of the main, left and right pulmonary arteries; 
2) to determine the inter- and intra-observer reducibility of our approach; 3) to determine 
associations between pulmonary artery volumes and COPD; and, 4) to evaluate pulmonary 
artery volumes as useful biomarkers for predicting COPD exacerbations.  
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In Chapter 2, we address objective 1 which focuses on the development of a three-
dimensional volumetric technique and on the assessment of its inter- and intra-observer 
reproducibility.  Briefly, to determine the volume, we manually outlined the cross-sectional 
area of each artery in a series of slices perpendicular to the longitudinal axis of the vessel.  
Summing the products of each area and inter-slice distance resulted in a volume 
measurement for each vessel.  Total pulmonary artery volume was also calculated by taking 
the union of voxels enclosed by each of the three vessels and multiplying it by the voxel 
dimensions.  From five rounds of repeated measurements, performed by three observers, 
we showed that our technique was highly reproducible, with strong inter- and intra-
observer agreement between measurements.  To assess the inter- and intra-observer 
agreement, the coefficient of variation as well as the intraclass correlation coefficient was 
calculated from the five repeated rounds of measurements.  We also showed strong 
agreement between baseline and follow-up measurements performed by the same observer 
with four months between measurements.  
In Chapter 3, we address objective 2, which focuses on evaluating PA abnormalities in a 
group of ex-smokers.  Specifically, we: 1) compared pulmonary artery sizes between a 
group of never-smokers and a group of ex-smokers; 2) assessed the relationship between 
pulmonary artery volumes and measurements of lung function and structure; and, 3) 
assessed pulmonary artery volumes as potential biomarkers for predicting the occurrence 
of acute exacerbations.  We hypothesized that pulmonary artery volumes will be greater in 
ex-smokers as compared to never-smokers.  We expected pulmonary artery volumes to 
correlate with measurements of lung function and structure and that they would be a 
suitable biomarker for predicting exacerbations of COPD.  We observed that ex-smokers 
presented with higher artery volumes than did the never-smoker subject group.  When all 
ex-smokers were grouped together, we found significant positive correlations between 
VDP and MPA, LPA, RPA and TPA volumes.  Furthermore, multivariate regression 
analysis revealed total pulmonary artery volume to be a significant predictor of COPD 
exacerbations; however, this relationship should be tested in different subject groups to 
strengthen our finding.  
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 Limitations of Current Work  
It is important that we report the limitations that were encountered in developing the 
volumetric technique described in Chapter 2 as well as the clinical relationships described 
in Chapter 3.  Although measurements were reproducible with high inter- and intra-
observer agreement, when examining measurements performed by each observer in more 
detail, we found that most of the variability between measurements resulted from the angle 
at which the axes of segmentation were placed.  Better anatomical landmarks should be 
considered when placing the axes of segmentation to further improve the reproducibility 
of our technique.  Furthermore, manual segmentation makes this technique time consuming 
and laborious.  Automation of the technique would address this limitation.  Moreover, we 
must acknowledge the fact that the computed tomography images acquired for our subjects 
were intended for emphysema measurements of the lung.  For this reason, in several images 
it was difficult to distinguish the pulmonary artery from the surrounding tissue.  Contrast 
imaging using an iodine-based contrast agent would allow the pulmonary artery to be better 
defined from the surroundings and potentially improve the reproducibility of our technique. 
When assessing the relationship between pulmonary artery volumes and measurements of 
lung function and structure, we must acknowledge that our subject groups consisted of a 
relatively small sample size as compared to previous studies using the one-dimensional 
measurement.8  Thus, our technique should be extended to different subject groups to 
evaluate its association with COPD and its ability to predict exacerbations.  Furthermore, 
14 subjects were excluded from our analyses due to poor image quality, which often 
resulted from poor contrast between the pulmonary arteries and the surrounding tissue.  
Our study was limited to and only included those exacerbations that required 
hospitalizations.  Based on a previous study, about 50% of exacerbations go unreported.  
These events should be considered and included in future analyses.  Several studies have 
shown the relationship between pulmonary artery size and pulmonary hypertension.9-15  It 
has also been shown that individuals with pulmonary hypertension have an increased risk 
of experiencing a COPD exacerbation.6  While we sought to explore the relationship 
between pulmonary artery enlargement and COPD, it may be of importance to also include 
pulmonary artery pressure measurements in future analyses.  Unfortunately, right-heart 
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catheterization data was not collected for this group of patients and therefore pulmonary 
artery pressures could not be directly measured and included in our analyses. 
 Future work and Clinical Applications 
As previously mentioned, when assessing the relationship between pulmonary artery size 
and COPD, we were limited by a relatively small sample size for both the ex-smoker and 
the never-smoker subject group.  Wells et al. explored the relationship between pulmonary 
artery diameter and exacerbations in a large number of subjects.8  Future studies should 
consider assessing the relationship between pulmonary artery volumes and COPD 
exacerbations in a large number of subjects as well as in different subject groups, including 
healthy individuals. 
To our knowledge we are the first to consider a three-dimensional technique for assessing 
the size of the main, left and right pulmonary arteries.  As mentioned before, manual slice-
by-slice segmentation of the pulmonary arteries in cross-sectional planes to each vessel are 
time consuming and laborious.  The time taken to perform main, left and right pulmonary 
artery volume measurements for a single subject can take up to one hour.  The extensive 
amount of time required to analyze a single individual makes our technique unsuitable for 
large scale clinical trials.  Therefore, future work should focus on improving our technique 
by developing semi-automated or fully-automated algorithms to estimate the size of the 
pulmonary arteries.  Automation of this technique will reduce the user input required and 
would therefore significantly decrease the time taken to perform a measurement.  Such an 
improvement would allow pulmonary artery volumes to be measured in studies with larger 
sample sizes.  The use of iodine-based contrast agents may be considered in future studies 
to improve the contrast between the pulmonary arteries and the surrounding tissues.  This, 
in turn, may help with developing an appropriate automated algorithm which estimates the 
size of the pulmonary artery on a specific threshold and boundaries set by the user.  
Pulmonary hypertension is a known complication of COPD that results in an increase in 
morbidity and mortality.16  The current gold standard for assessing pulmonary hypertension 
is through right heart catheterization.9  This technique is invasive, generally causes 
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discomfort, and can lead to complications.  Recent studies have shown that the diameter of 
the pulmonary artery measured at the level of the bifurcation has the ability to predict 
borderline pulmonary hypertension.9-15  We believe that our three-dimensional volumetric 
technique may be more sensitive to morphological changes in the pulmonary artery and 
should therefore be assessed as a potential diagnostic tool in predicting pulmonary 
hypertension.  This would provide a non-invasive method for assessing and monitoring 
patients at risk of pulmonary hypertension.  Therefore, future studies should assess the 
relationship between pulmonary artery pressures measured by right heart catheterization 
and pulmonary artery volumes measured using our technique. 
 
Future studies should also focus on developing MRI imaging techniques for evaluating the 
size of the pulmonary arteries.  This development would allow for repeated measurements 
to be performed and would therefore permit evaluation of disease progression and 
treatment response.  MRI provides high soft tissue contrast which may yield useful 
information in developing future measurements of the pulmonary arteries.  Being able to 
differentiate between the lumen of the vessel and the arterial wall could reveal useful 
information about pulmonary artery abnormalities.   
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